ガンシクロビル
Based on 28 publication(s) in Google Scholar
Ganciclovir (BW 759), a nucleoside analogue, is an orally active antiviral agent with activity against CMV. Ganciclovir also has activity in vitro against members of the herpes group and some other DNA viruses. Ganciclovir inhibits the in vitro replication of human herpes viruses (HSV 1 and 2, CMV) and adenovirus serotypes 1, 2, 4, 6, 8, 10, 19, 22 and 28. Ganciclovir has an IC50 of 5.2 μM for feline herpesvirus type-1 (FHV-1) and can diffuse into the brain.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.89%
- CAS 番号: 82410-32-0
- 分子式: C9H13N5O4
- 分子量:255.23
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
MedChemExpress(MCE)の使用を引用している文献 Ganciclovir
More- Cell. 2025 Apr 3;188(7):1828-1841.e15. [Abstract]
- Cell. 2020 Nov 25;183(5):1402-1419.e18. [Abstract]
- Nat Neurosci. 2024 Aug;27(8):1522-1533. [Abstract]
- Nat Commun. 2024 Apr 17;15(1):3311. [Abstract]
- Trends Biotechnol. 2025 Aug 29:S0167-7799(25)00316-6. [Abstract]
- J Nanobiotechnology. 2022 Jul 20;20(1):340. [Abstract]
- Brain Behav Immun. 2019 Aug:80:394-405. [Abstract]
- Sci Data. 2022 Oct 8;9(1):610. [Abstract]
- Biochem Pharmacol. 2022 Mar:197:114917. [Abstract]
- Pharmaceutics. 2023 Nov 27;15(12):2680. [Abstract]
- Cells. 2019 Dec 20;9(1):31. [Abstract]
- Microchem J. 2021, 106587.
- PLoS Pathog. 2024 Apr 16;20(4):e1012141. [Abstract]
- Pharmaceuticals (Basel). 2025 Oct 16;18(10):1560. [Abstract]
- Eur J Pharm Sci. 2019 Jan 15:127:29-37. [Abstract]
- J Gen Virol. 2026 Mar;107(3):002248. [Abstract]
- Antiviral Res. 2021 Sep:193:105124. [Abstract]
- J Virol. 2017 Jan 18;91(3). pii: e02152-16. [Abstract]
- Stem Cells. 2025 Jun 24;43(7):sxaf032. [Abstract]
- Microb Pathog. 2026 Apr:213:108349. [Abstract]
- Am J Physiol Gastrointest Liver Physiol. 2026 May 1;330(5):G532-G548. [Abstract]
- Pharmacol Res Perspect. 2020 Apr;8(2):e00575. [Abstract]
- bioRxiv. 2026 Jun 2.
- New York University. 2026.
- Preprints. 2025 Dec 2.
- bioRxiv. 2025 Nov 13:2025.11.11.687828. [Abstract]
- bioRxiv. 2023 Sep 20.
- Research Square Print. 2023 Mar.
-
Bio/Physico-chemical Assay
-
Others
-
Microbiological Assay
-
Bio/Physico-chemical Assay
-
Cell Proliferation/Viability Assay
Antibiotic アイソフォーム固有の製品をすべて表示
More
生物活性
|
CMV |
HSV-1 |
HSV-2 |
FHV-1 5.2 μM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BC-3 | IC50 |
70 μM
Compound: GCV
|
Cytotoxicity against Kaposi's sarcoma-associated herpesvirus infected BC3 cells after 120 hrs by MTT assay
Cytotoxicity against Kaposi's sarcoma-associated herpesvirus infected BC3 cells after 120 hrs by MTT assay
|
[PMID: 17402726] |
| BJ | EC50 |
3 μM
Compound: GCV
|
Antiviral activity against Human cytomegalovirus Towne infected in human hhTERT-BJ1 cells assessed as inhibition of virus mediated DNA synthesis after 2 days
Antiviral activity against Human cytomegalovirus Towne infected in human hhTERT-BJ1 cells assessed as inhibition of virus mediated DNA synthesis after 2 days
|
[PMID: 18458124] |
| Bone marrow cell | CC50 |
30 μM
Compound: ganciclovir
|
Cytotoxicity against human bone marrow cells assessed as inhibition of CFU-GM formation after 15 days
Cytotoxicity against human bone marrow cells assessed as inhibition of CFU-GM formation after 15 days
|
[PMID: 17329103] |
| BSC-1 | IC50 |
3.5 μM
Compound: Ganciclovir
|
Antiviral activity against HSV-1 (herpes simplex virus), determined by ELISA in quadruplicate wells using BSC-1 cells
Antiviral activity against HSV-1 (herpes simplex virus), determined by ELISA in quadruplicate wells using BSC-1 cells
|
[PMID: 10882370] |
| BSC-1 | IC50 |
3.5 μM
Compound: Ganciclovir
|
ELISA assay was performed using BSC-1 cells to determine activity against HSV-1
ELISA assay was performed using BSC-1 cells to determine activity against HSV-1
|
[PMID: 10882372] |
| BSC-1 | IC50 |
3.5 μM
Compound: GCV (ganciclovir) (table-1)
|
Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay
Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay
|
[PMID: 15509174] |
| BSC-1 | IC50 |
3.5 μM
Compound: GCV (ganciclovir) (table-1)
|
Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay
Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay
|
[PMID: 15509175] |
| BSC-1 | IC50 |
3.5 μM
Compound: GCV (table-1)
|
Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay
Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay
|
[PMID: 15509176] |
| BSC-1 | IC50 |
>100 μM
Compound: Ganciclovir
|
Tested in vitro for cytotoxicity against the monkey kidney cells (BSC-1 cells).
Tested in vitro for cytotoxicity against the monkey kidney cells (BSC-1 cells).
|
[PMID: 2175356] |
| BSC-1 | IC50 |
>100 μM
Compound: Ganciclovir (DHPG)
|
Cytotoxicity against Monkey kidney cells(BSC-1 cells)
Cytotoxicity against Monkey kidney cells(BSC-1 cells)
|
[PMID: 2500527] |
| BSC-1 | IC50 |
>100 μM
Compound: ganciclovir
|
The compound was tested for cytotoxicity against BSC1 cell
The compound was tested for cytotoxicity against BSC1 cell
|
[PMID: 2840500] |
| BSC-1 | IC50 |
3 μM
Compound: Ganciclovir
|
Antiviral activity of the compound was evaluated against the Herpes simplex virus type-1 in BSC-1 cells
Antiviral activity of the compound was evaluated against the Herpes simplex virus type-1 in BSC-1 cells
|
[PMID: 2913300] |
| BSC-1 | IC50 |
3.5 μM
Compound: 1
|
In vitro antiviral activity against HSV-1 virus in BSC-1 (monkey kidney) cells.
In vitro antiviral activity against HSV-1 virus in BSC-1 (monkey kidney) cells.
|
[PMID: 9057865] |
| carcinoma cell line | IC50 |
>100 μM
Compound: Ganciclovir
|
Compound was tested for inhibition activity of human oral carcinoma cell line (KB ) cells in quadruplicate assay.
Compound was tested for inhibition activity of human oral carcinoma cell line (KB ) cells in quadruplicate assay.
|
[PMID: 10882375] |
| CCRF-CEM | IC50 |
>390 μM
Compound: Ganciclovir
|
In vitro anti-HIV screen using HIV-1 infected CD4 lymphocytes (CEM cell line), determines cytotoxicity
In vitro anti-HIV screen using HIV-1 infected CD4 lymphocytes (CEM cell line), determines cytotoxicity
|
[PMID: 11814776] |
| CCRF-CEM | CC50 |
>200 μM
Compound: Ganciclovir
|
Compound concentration required to reduce viability of CEM cells
Compound concentration required to reduce viability of CEM cells
|
[PMID: 14643328] |
| CCRF-CEM | EC50 |
>200 μM
Compound: Ganciclovir
|
Compound was tested for anti-viral activity against HIV-1 in CEM cells
Compound was tested for anti-viral activity against HIV-1 in CEM cells
|
[PMID: 14643328] |
| CCRF-CEM | EC50 |
>200 μM
Compound: Ganciclovir
|
Compound was tested for anti-viral activity against HIV-2 in CEM cells
Compound was tested for anti-viral activity against HIV-2 in CEM cells
|
[PMID: 14643328] |
| CCRF-CEM | CC50 |
5 μM
Compound: ganciclovir
|
Cytotoxicity against CEM cells
Cytotoxicity against CEM cells
|
[PMID: 15615545] |
| CCRF-CEM | EC50 |
>50 μM
Compound: Gancyclovir
|
Antiviral activity against HIV1 IIIB in CEM cells
Antiviral activity against HIV1 IIIB in CEM cells
|
[PMID: 16392791] |
| CCRF-CEM | EC50 |
>50 μM
Compound: Gancyclovir
|
Antiviral activity against HIV2 ROD in CEM cells
Antiviral activity against HIV2 ROD in CEM cells
|
[PMID: 16392791] |
| CCRF-CEM | CC50 |
>100 μM
Compound: 1
|
Cytostatic activity human CEM cells assessed as reduction in cell viability after 72 hrs by cell counting method
Cytostatic activity human CEM cells assessed as reduction in cell viability after 72 hrs by cell counting method
|
[PMID: 28829913] |
| CCRF-HSB-2 | IC50 |
17 μg/mL
Compound: DHPG
|
Antiproliferative effects on CCRF-HSB-2 (human leukemia) cells.
Antiproliferative effects on CCRF-HSB-2 (human leukemia) cells.
|
[PMID: 9216836] |
| CFU-GM | IC50 |
19 μM
Compound: Ganciclovir
|
In vitro toxicity against colony forming unit granulocyte macrophage (CFU-GM)
In vitro toxicity against colony forming unit granulocyte macrophage (CFU-GM)
|
[PMID: 8176714] |
| DG-75 | IC50 |
>100 μM
Compound: GCV
|
Cytotoxicity against DG75 cells after 120 hrs by MTT assay
Cytotoxicity against DG75 cells after 120 hrs by MTT assay
|
[PMID: 17402726] |
| E6SM | EC50 |
>100 μM
Compound: Gancyclovir, DHPG
|
Effective concentration required to inhibit Vaccinia virus-induced cytopathicity by 50% in E6SM cell lines
Effective concentration required to inhibit Vaccinia virus-induced cytopathicity by 50% in E6SM cell lines
|
[PMID: 11495586] |
| E6SM | EC50 |
0.0012 μM
Compound: Gancyclovir, DHPG
|
Effective concentration required to inhibit Herpes simplex virus-1 (HSV-1) induced cytopathicity by 50% in E6SM cell lines
Effective concentration required to inhibit Herpes simplex virus-1 (HSV-1) induced cytopathicity by 50% in E6SM cell lines
|
[PMID: 11495586] |
| E6SM | EC50 |
0.0012 μM
Compound: Gancyclovir, DHPG
|
Effective concentration required to inhibit Herpes simplex virus-2 (HSV-2) induced cytopathicity by 50% in E6SM cell lines
Effective concentration required to inhibit Herpes simplex virus-2 (HSV-2) induced cytopathicity by 50% in E6SM cell lines
|
[PMID: 11495586] |
| E6SM | EC50 |
>100 μg/mL
Compound: Ganciclovir
|
Inhibitory activity against vaccinia virus (VV) replication in E6SM cell cultures of human embryonic skin-muscle
Inhibitory activity against vaccinia virus (VV) replication in E6SM cell cultures of human embryonic skin-muscle
|
[PMID: 12459010] |
| E6SM | EC50 |
>100 μg/mL
Compound: Ganciclovir
|
Inhibitory activity against vesicular stomatitis virus (VSV) replication in E6SM cell cultures of human embryonic skin-muscle
Inhibitory activity against vesicular stomatitis virus (VSV) replication in E6SM cell cultures of human embryonic skin-muscle
|
[PMID: 12459010] |
| E6SM | EC50 |
0.019 μg/mL
Compound: Ganciclovir
|
Inhibitory activity against HSV-1 (F) replication in E6SM cell cultures of human embryonic skin-muscle
Inhibitory activity against HSV-1 (F) replication in E6SM cell cultures of human embryonic skin-muscle
|
[PMID: 12459010] |
| E6SM | EC50 |
0.019 μg/mL
Compound: Ganciclovir
|
Inhibitory activity against HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle
Inhibitory activity against HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle
|
[PMID: 12459010] |
| E6SM | EC50 |
0.019 μg/mL
Compound: Ganciclovir
|
Inhibitory activity against HSV-1 (McIntyre) replication in E6SM cell cultures of human embryonic skin-muscle
Inhibitory activity against HSV-1 (McIntyre) replication in E6SM cell cultures of human embryonic skin-muscle
|
[PMID: 12459010] |
| E6SM | EC50 |
0.019 μg/mL
Compound: Ganciclovir
|
Inhibitory activity against HSV-2 (G) replication in E6SM cell cultures of human embryonic skin-muscle
Inhibitory activity against HSV-2 (G) replication in E6SM cell cultures of human embryonic skin-muscle
|
[PMID: 12459010] |
| E6SM | EC50 |
0.019 μg/mL
Compound: Ganciclovir
|
Inhibitory activity against HSV-2 (Lyons) replication in E6SM cell cultures of human embryonic skin-muscle
Inhibitory activity against HSV-2 (Lyons) replication in E6SM cell cultures of human embryonic skin-muscle
|
[PMID: 12459010] |
| E6SM | EC50 |
0.032 μg/mL
Compound: Ganciclovir
|
Inhibitory activity against HSV-2 (196) replication in E6SM cell cultures of human embryonic skin-muscle
Inhibitory activity against HSV-2 (196) replication in E6SM cell cultures of human embryonic skin-muscle
|
[PMID: 12459010] |
| E6SM | EC50 |
2.4 μg/mL
Compound: Ganciclovir
|
Inhibitory activity against TK-deficient HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle
Inhibitory activity against TK-deficient HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle
|
[PMID: 12459010] |
| E6SM | EC50 |
>100 μg/mL
Compound: ganciclovir
|
Effective concentration required to reduce vaccinia virus plaque formation by 50% in E6SM Cell Culture
Effective concentration required to reduce vaccinia virus plaque formation by 50% in E6SM Cell Culture
|
[PMID: 15481985] |
| E6SM | EC50 |
0.003 μg/mL
Compound: ganciclovir
|
Effective concentration required to reduce HSV-2 strain G virus plaque formation by 50% in E6SM Cell Culture
Effective concentration required to reduce HSV-2 strain G virus plaque formation by 50% in E6SM Cell Culture
|
[PMID: 15481985] |
| E6SM | EC50 |
0.004 μg/mL
Compound: ganciclovir
|
Effective concentration required to reduce HSV-1 strain KOS virus plaque formation by 50% in E6SM Cell Culture
Effective concentration required to reduce HSV-1 strain KOS virus plaque formation by 50% in E6SM Cell Culture
|
[PMID: 15481985] |
| E6SM | EC50 |
2.4 μg/mL
Compound: ganciclovir
|
Effective concentration required to reduce HSV-1 strain KOS ACV virus plaque formation by 50% in E6SM Cell Culture
Effective concentration required to reduce HSV-1 strain KOS ACV virus plaque formation by 50% in E6SM Cell Culture
|
[PMID: 15481985] |
| E6SM | EC50 |
>100 μg/mL
Compound: ganciclovir
|
Antiviral activity against Vaccinia virus in E6SM cells assessed as reduction of virus-induced cytopathogenicity
Antiviral activity against Vaccinia virus in E6SM cells assessed as reduction of virus-induced cytopathogenicity
|
[PMID: 17518459] |
| E6SM | EC50 |
0.002 μg/mL
Compound: ganciclovir
|
Antiviral activity against HSV1 KOS in E6SM cells assessed as reduction of virus-induced cytopathogenicity
Antiviral activity against HSV1 KOS in E6SM cells assessed as reduction of virus-induced cytopathogenicity
|
[PMID: 17518459] |
| E6SM | EC50 |
0.007 μg/mL
Compound: ganciclovir
|
Antiviral activity against HSV2 G in E6SM cells assessed as reduction of virus-induced cytopathogenicity
Antiviral activity against HSV2 G in E6SM cells assessed as reduction of virus-induced cytopathogenicity
|
[PMID: 17518459] |
| E6SM | EC50 |
0.02 μg/mL
Compound: ganciclovir
|
Antiviral activity against thymidine kinase deficient HSV1 VMW1837 in E6SM cells assessed as reduction of virus-induced cytopathogenicity
Antiviral activity against thymidine kinase deficient HSV1 VMW1837 in E6SM cells assessed as reduction of virus-induced cytopathogenicity
|
[PMID: 17518459] |
| E6SM | EC50 |
0.7 μg/mL
Compound: ganciclovir
|
Antiviral activity against thymidine kinase-deficient HSV1 B2006 in E6SM cells assessed as reduction of virus-induced cytopathogenicity
Antiviral activity against thymidine kinase-deficient HSV1 B2006 in E6SM cells assessed as reduction of virus-induced cytopathogenicity
|
[PMID: 17518459] |
| E6SM | CC50 |
>100 μg/mL
Compound: ganciclovir
|
Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of E6SM cells
Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of E6SM cells
|
[PMID: 8709116] |
| Fibroblast | IC50 |
156 μM
Compound: GCV
|
Inhibitory activity against human foreskin fibroblast cell proliferation
Inhibitory activity against human foreskin fibroblast cell proliferation
|
[PMID: 11708924] |
| Fibroblast | EC50 |
0.04 μM
Compound: 10
|
Antiviral activity against Human cytomegalovirus AD169 infected in human foreskin fibroblast cells assessed as inhibition of virus-induced cytopathic effect
Antiviral activity against Human cytomegalovirus AD169 infected in human foreskin fibroblast cells assessed as inhibition of virus-induced cytopathic effect
|
[PMID: 19397271] |
| Fibroblast | EC50 |
1.2 μM
Compound: 10
|
Antiviral activity against Human cytomegalovirus Towne infected in human foreskin fibroblast cells by plaque reduction assay
Antiviral activity against Human cytomegalovirus Towne infected in human foreskin fibroblast cells by plaque reduction assay
|
[PMID: 19397271] |
| Fibroblast | EC50 |
5.5 μM
Compound: 10
|
Antiviral activity against Murine cytomegalovirus infected in mouse embryonic fibroblast cells by plaque reduction assay
Antiviral activity against Murine cytomegalovirus infected in mouse embryonic fibroblast cells by plaque reduction assay
|
[PMID: 19397271] |
| Fibroblast | IC50 |
>100 μM
Compound: Ganciclovir (DHPG)
|
Cytotoxicity against Normal human diploid cells (human foreskin fibroblasts cells)
Cytotoxicity against Normal human diploid cells (human foreskin fibroblasts cells)
|
[PMID: 2500527] |
| Fibroblast | IC50 |
0.05 μM
Compound: 1 (BW-B759U, ganciclovir)
|
Inhibition of growth of Epstein Barr virus(EBV) in human lung fibroblast cell line
Inhibition of growth of Epstein Barr virus(EBV) in human lung fibroblast cell line
|
[PMID: 2826784] |
| Fibroblast | IC50 |
3.4 μM
Compound: 1 (BW-B759U, ganciclovir)
|
Inhibition of growth of human cytomegalovirus (HCMV) was determined by plaque reduction assay in human lung fibroblast cell line
Inhibition of growth of human cytomegalovirus (HCMV) was determined by plaque reduction assay in human lung fibroblast cell line
|
[PMID: 2826784] |
| Fibroblast | IC50 |
168 μM
Compound: ganciclovir
|
Concentration of the drug required to reduce the proliferation of human foreskin fibroblast cells
Concentration of the drug required to reduce the proliferation of human foreskin fibroblast cells
|
[PMID: 8394933] |
| HEL | CC50 |
>50 μg/mL
Compound: Ganciclovir
|
The concentration required to reduce cell growth by 50% was measured on Human Embryonic Lung (HEL) cells
The concentration required to reduce cell growth by 50% was measured on Human Embryonic Lung (HEL) cells
|
[PMID: 10197958] |
| HEL | IC50 |
>50 μM
Compound: DHPG
|
The compound was tested for cytotoxic concentration required to reduce human embryonic lung cell growth by 50%
The compound was tested for cytotoxic concentration required to reduce human embryonic lung cell growth by 50%
|
[PMID: 10411487] |
| HEL | IC50 |
>50 μM
Compound: DHPG
|
Minimum cytotoxic concentration that causes a microscopically detectable alteration of cell morphology in human embryonic lung cells
Minimum cytotoxic concentration that causes a microscopically detectable alteration of cell morphology in human embryonic lung cells
|
[PMID: 10411487] |
| HEL | IC50 |
1 μM
Compound: DHPG
|
The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against cytomegalo virus AD-169 strain
The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against cytomegalo virus AD-169 strain
|
[PMID: 10411487] |
| HEL | IC50 |
5 μM
Compound: DHPG
|
The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against cytomegalo virus Davis strain
The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against cytomegalo virus Davis strain
|
[PMID: 10411487] |
| HEL | CC50 |
394 μM
Compound: ganciclovir
|
Inhibition of cell growth in HEL cells.
Inhibition of cell growth in HEL cells.
|
[PMID: 10966745] |
| HEL | EC50 |
11.8 μM
Compound: Gancyclovir, DHPG
|
Effective concentration required to inhibit cytomegalo virus-induced cytopathicity by 50% in Davis-169 strain HEL cell lines
Effective concentration required to inhibit cytomegalo virus-induced cytopathicity by 50% in Davis-169 strain HEL cell lines
|
[PMID: 11495586] |
| HEL | EC50 |
7.8 μM
Compound: Gancyclovir, DHPG
|
Effective concentration required to inhibit cytomegalo virus-induced cytopathicity by 50% in AD-169 strain HEL cell lines
Effective concentration required to inhibit cytomegalo virus-induced cytopathicity by 50% in AD-169 strain HEL cell lines
|
[PMID: 11495586] |
| HEL | CC50 |
>50 μg/mL
Compound: Ganciclovir
|
Cytotoxic concentration reducing HEL cell growth by 50%.
Cytotoxic concentration reducing HEL cell growth by 50%.
|
[PMID: 12217359] |
| HEL | CC50 |
>400 μM
Compound: Ganciclovir
|
Compound concentration required to reduce viability of HEL cells
Compound concentration required to reduce viability of HEL cells
|
[PMID: 14643328] |
| HEL | EC50 |
0.06 μM
Compound: Ganciclovir
|
Compound was tested for anti-viral activity against HSV-1(G) in HEL cells
Compound was tested for anti-viral activity against HSV-1(G) in HEL cells
|
[PMID: 14643328] |
| HEL | CC50 |
>150 μM
Compound: Ganciclovir
|
Concentration required against HEL cell proliferation
Concentration required against HEL cell proliferation
|
[PMID: 14643358] |
| HEL | CC50 |
>150 μM
Compound: Ganciclovir
|
Cytostatic concentration required to inhibit HEL cell proliferation measured at day 4
Cytostatic concentration required to inhibit HEL cell proliferation measured at day 4
|
[PMID: 15027877] |
| HEL | EC50 |
2.7 μM
Compound: Ganciclovir
|
Effective concentration required to inhibit HCMV AD169 strain-induced cytopathicity in human embryonic lung (HEL) fibroblast cell cultures at day 7 of postinfection
Effective concentration required to inhibit HCMV AD169 strain-induced cytopathicity in human embryonic lung (HEL) fibroblast cell cultures at day 7 of postinfection
|
[PMID: 15027877] |
| HEL | EC50 |
3.9 μM
Compound: Ganciclovir
|
Effective concentration required to inhibit HCMV Davis strain-induced cytopathicity in human embryonic lung (HEL) fibroblast cell cultures at day 7 of postinfection
Effective concentration required to inhibit HCMV Davis strain-induced cytopathicity in human embryonic lung (HEL) fibroblast cell cultures at day 7 of postinfection
|
[PMID: 15027877] |
| HEL | CC50 |
>150 μM
Compound: DHPG(ganciclovir)
|
Cytotoxic concentration required to reduce HEL cell growth by 50%
Cytotoxic concentration required to reduce HEL cell growth by 50%
|
[PMID: 15081019] |
| HEL | EC50 |
0.8 μM
Compound: DHPG(ganciclovir)
|
Effective concentration against human cytomegalovirus Davies strain in HEL cell cultures
Effective concentration against human cytomegalovirus Davies strain in HEL cell cultures
|
[PMID: 15081019] |
| HEL | EC50 |
0.9 μM
Compound: DHPG(ganciclovir)
|
Effective concentration against human cytomegalovirus AD-169 strain in HEL cell cultures
Effective concentration against human cytomegalovirus AD-169 strain in HEL cell cultures
|
[PMID: 15081019] |
| HEL | CC50 |
>150 μM
Compound: ganciclovir
|
Cytotoxic concentration required to reduce HEL cell growth by 50%
Cytotoxic concentration required to reduce HEL cell growth by 50%
|
[PMID: 15481985] |
| HEL | EC50 |
0.5 μM
Compound: ganciclovir
|
Effective concentration required to reduce CMV AD169 strain virus plaque formation by 50% in HEL cell culture
Effective concentration required to reduce CMV AD169 strain virus plaque formation by 50% in HEL cell culture
|
[PMID: 15481985] |
| HEL | EC50 |
1.5 μM
Compound: ganciclovir
|
Effective concentration required to reduce CMV davis strain virus plaque formation by 50% in HEL cell culture
Effective concentration required to reduce CMV davis strain virus plaque formation by 50% in HEL cell culture
|
[PMID: 15481985] |
| HEL | EC50 |
0.06 μM
Compound: Gancyclovir
|
Effective concentration required to inhibit herpes simplex virus type 1 Kos strain induced cytopathicity in Hel cells
Effective concentration required to inhibit herpes simplex virus type 1 Kos strain induced cytopathicity in Hel cells
|
[PMID: 15658858] |
| HEL | CC50 |
65.4 μg/mL
Compound: GCV (Ganciclovir)
|
Cytotoxic concentration to reduce the 50% cell growth of human embryonic lung cells
Cytotoxic concentration to reduce the 50% cell growth of human embryonic lung cells
|
[PMID: 15658861] |
| HEL | EC50 |
0.37 μg/mL
Compound: Ganciclovir
|
Effective concentration against AD-169 strain of CMV virus expressed in HEL cells
Effective concentration against AD-169 strain of CMV virus expressed in HEL cells
|
[PMID: 15689173] |
| HEL | EC50 |
0.37 μg/mL
Compound: Ganciclovir
|
Effective concentration against Davis strain of CMV virus expressed in HEL cells
Effective concentration against Davis strain of CMV virus expressed in HEL cells
|
[PMID: 15689173] |
| HEL | IC50 |
2.7 μg/mL
Compound: Ganciclovir
|
Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory strains Davis using HEL cell line
Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory strains Davis using HEL cell line
|
[PMID: 15745823] |
| HEL | CC50 |
>150 μM
Compound: Ganciclovir
|
Cytotoxic concentration required to reduce HEL cell growth
Cytotoxic concentration required to reduce HEL cell growth
|
[PMID: 15801851] |
| HEL | EC50 |
1.5 μM
Compound: Ganciclovir
|
Effective concentration required to inhibit human cytomegalo virus AD-169 induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection
Effective concentration required to inhibit human cytomegalo virus AD-169 induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection
|
[PMID: 15801851] |
| HEL | EC50 |
1.5 μM
Compound: Ganciclovir
|
Effective concentration required to inhibit human cytomegalo virus Davis induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection
Effective concentration required to inhibit human cytomegalo virus Davis induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection
|
[PMID: 15801851] |
| HEL | EC50 |
0.06 μM
Compound: Gancyclovir
|
Antiviral activity against HSV1 KOS in HEL cells
Antiviral activity against HSV1 KOS in HEL cells
|
[PMID: 16392791] |
| HEL | EC50 |
0.06 μM
Compound: Gancyclovir
|
Antiviral activity against HSV2 G in HEL cells
Antiviral activity against HSV2 G in HEL cells
|
[PMID: 16392791] |
| HEL | CC50 |
>197 μM
Compound: GCV
|
Cytotoxic activity against cultured human embryonic lung (HEL) cells
Cytotoxic activity against cultured human embryonic lung (HEL) cells
|
[PMID: 16392824] |
| HEL | CC50 |
34 μg/mL
Compound: ganciclovir
|
Cytotoxicity against HEL cells
Cytotoxicity against HEL cells
|
[PMID: 16480257] |
| HEL | CC50 |
>100 μM
Compound: Gancyclovir
|
Cytotoxicity against HEL cells
Cytotoxicity against HEL cells
|
[PMID: 17181162] |
| HEL | EC50 |
>100 μM
Compound: Gancyclovir
|
Antiviral activity against vaccinia virus in HEL cells
Antiviral activity against vaccinia virus in HEL cells
|
[PMID: 17181162] |
| HEL | EC50 |
>100 μM
Compound: Gancyclovir
|
Antiviral activity against vesicular somatitis virus in HEL cells
Antiviral activity against vesicular somatitis virus in HEL cells
|
[PMID: 17181162] |
| HEL | EC50 |
0.032 μM
Compound: Gancyclovir
|
Antiviral activity against HSV2 in HEL cells
Antiviral activity against HSV2 in HEL cells
|
[PMID: 17181162] |
| HEL | EC50 |
0.0014 μg/mL
Compound: ganciclovir
|
Antiviral activity against HSV2 Lyons in HEL cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against HSV2 Lyons in HEL cells assessed as inhibition of virus-induced cytopathicity
|
[PMID: 17298047] |
| HEL | EC50 |
0.0096 μg/mL
Compound: ganciclovir
|
Antiviral activity against HSV2 G in HEL cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against HSV2 G in HEL cells assessed as inhibition of virus-induced cytopathicity
|
[PMID: 17298047] |
| HEL | EC50 |
0.91 μg/mL
Compound: ganciclovir
|
Antiviral activity against ACV-resistant TK- HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against ACV-resistant TK- HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity
|
[PMID: 17298047] |
| HEL | EC50 |
1.5 μg/mL
Compound: ganciclovir
|
Antiviral activity against HCMV AD169 in HEL cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against HCMV AD169 in HEL cells assessed as inhibition of virus-induced cytopathicity
|
[PMID: 17298047] |
| HEL | EC50 |
1.5 μg/mL
Compound: ganciclovir
|
Antiviral activity against HCMV Davis in HEL cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against HCMV Davis in HEL cells assessed as inhibition of virus-induced cytopathicity
|
[PMID: 17298047] |
| HEL | EC50 |
0.00038 μg/mL
Compound: ganciclovir
|
Antiviral activity against HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity
|
[PMID: 17298047] |
| HEL | EC50 |
0.38 ng/mL
Compound: ganciclovir
|
Antiviral activity against HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity
|
[PMID: 17298047] |
| HEL | EC50 |
2.75 μM
Compound: ganciclovir
|
Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation
Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation
|
[PMID: 17518459] |
| HEL | EC50 |
6.3 μM
Compound: ganciclovir
|
Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation
Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation
|
[PMID: 17518459] |
| HEL | CC50 |
172 μM
Compound: ganciclovir
|
Cytotoxicity against HEL cells assessed as cell growth after 7 days
Cytotoxicity against HEL cells assessed as cell growth after 7 days
|
[PMID: 17539622] |
| HEL | EC50 |
1.3 μM
Compound: ganciclovir
|
Antiviral activity against human cytomegalovirus Davis in HEL cells assessed as reduction of plaque formation after 7days
Antiviral activity against human cytomegalovirus Davis in HEL cells assessed as reduction of plaque formation after 7days
|
[PMID: 17539622] |
| HEL | EC50 |
4.8 μM
Compound: ganciclovir
|
Antiviral activity against human cytomegalovirus AD169 in HEL cells assessed as reduction of plaque formation after 7 days
Antiviral activity against human cytomegalovirus AD169 in HEL cells assessed as reduction of plaque formation after 7 days
|
[PMID: 17539622] |
| HEL | CC50 |
87 μg/mL
Compound: Ganciclovir
|
Cytotoxicity against human HEL cells assessed as reduction of cell growth
Cytotoxicity against human HEL cells assessed as reduction of cell growth
|
[PMID: 17583388] |
| HEL | EC50 |
0.64 μg/mL
Compound: Ganciclovir
|
Antiviral activity against human cytomegalovirus AD169 infected HEL cells assessed as reduction in virus plaque formation
Antiviral activity against human cytomegalovirus AD169 infected HEL cells assessed as reduction in virus plaque formation
|
[PMID: 17583388] |
| HEL | EC50 |
1.9 μg/mL
Compound: Ganciclovir
|
Antiviral activity against human cytomegalovirus Davis infected HEL cells assessed as reduction in virus plaque formation
Antiviral activity against human cytomegalovirus Davis infected HEL cells assessed as reduction in virus plaque formation
|
[PMID: 17583388] |
| HEL | CC50 |
>200 μM
Compound: GCV
|
Cytotoxicity against HEL cells after 3 days
Cytotoxicity against HEL cells after 3 days
|
[PMID: 17622128] |
| HEL | EC50 |
2.3 μM
Compound: GCV
|
Antiviral activity against TK+ VZV YS in HEL cells assessed as reduction of virus plaque formation after 5 days
Antiviral activity against TK+ VZV YS in HEL cells assessed as reduction of virus plaque formation after 5 days
|
[PMID: 17622128] |
| HEL | EC50 |
5.1 μM
Compound: GCV
|
Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 7 days
Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 7 days
|
[PMID: 17622128] |
| HEL | EC50 |
8.7 μM
Compound: GCV
|
Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 7 days
Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 7 days
|
[PMID: 17622128] |
| HEL | CC50 |
262 μM
Compound: ganciclovir
|
Cytotoxicity against human HEL cells assessed as reduction of cell growth
Cytotoxicity against human HEL cells assessed as reduction of cell growth
|
[PMID: 17672445] |
| HEL | EC50 |
2.6 μM
Compound: ganciclovir
|
Antiviral activity against CMV Davis in human HEL cells after 7 days
Antiviral activity against CMV Davis in human HEL cells after 7 days
|
[PMID: 17672445] |
| HEL | EC50 |
6.5 μM
Compound: ganciclovir
|
Antiviral activity against CMV AD169 in human HEL cells after 7 days
Antiviral activity against CMV AD169 in human HEL cells after 7 days
|
[PMID: 17672445] |
| HEL | CC50 |
146 μg/mL
Compound: ganciclovir
|
Cytotoxicity against HEL cells assessed as reduction of cell growth after 3 days
Cytotoxicity against HEL cells assessed as reduction of cell growth after 3 days
|
[PMID: 17869124] |
| HEL | EC50 |
0.51 μg/mL
Compound: ganciclovir
|
Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 5 days
Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 5 days
|
[PMID: 17869124] |
| HEL | EC50 |
0.8 μg/mL
Compound: ganciclovir
|
Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 5 days
Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 5 days
|
[PMID: 17869124] |
| HEL | CC50 |
122 μg/mL
Compound: gancyclovir
|
Cytotoxicity against HEL cells assessed as cell growth after 3 days
Cytotoxicity against HEL cells assessed as cell growth after 3 days
|
[PMID: 17948980] |
| HEL | EC50 |
0.0014 μg/mL
Compound: gancyclovir
|
Antiviral activity against HSV2 Lyons in HEL cells assessed as reduction of virus-induced cytopathogenicity
Antiviral activity against HSV2 Lyons in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
[PMID: 17948980] |
| HEL | EC50 |
0.0036 μg/mL
Compound: gancyclovir
|
Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity
Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
[PMID: 17948980] |
| HEL | EC50 |
0.9 μg/mL
Compound: gancyclovir
|
Antiviral activity against acyclovir-resistant HSV1 KOS TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity
Antiviral activity against acyclovir-resistant HSV1 KOS TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
[PMID: 17948980] |
| HEL | EC50 |
1.29 μg/mL
Compound: gancyclovir
|
Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus-induced cytopathogenicity
Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
[PMID: 17948980] |
| HEL | EC50 |
1.68 μg/mL
Compound: gancyclovir
|
Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus-induced cytopathogenicity
Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
[PMID: 17948980] |
| HEL | EC50 |
0.00056 μg/mL
Compound: gancyclovir
|
Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity
Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
[PMID: 17948980] |
| HEL | EC50 |
0.56 ng/mL
Compound: gancyclovir
|
Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity
Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
[PMID: 17948980] |
| HEL | CC50 |
172 μM
Compound: ganciclovir
|
Cytotoxicity against HEL cells assessed as reduction in cell growth
Cytotoxicity against HEL cells assessed as reduction in cell growth
|
[PMID: 17961851] |
| HEL | EC50 |
1.3 μM
Compound: ganciclovir
|
Antiviral activity against HCMV Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days
Antiviral activity against HCMV Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days
|
[PMID: 17961851] |
| HEL | EC50 |
4.8 μM
Compound: ganciclovir
|
Antiviral activity against HCMV AD169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days
Antiviral activity against HCMV AD169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days
|
[PMID: 17961851] |
| HEL | EC50 |
0.54 μg/mL
Compound: GCV
|
Antiviral activity against acyclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
Antiviral activity against acyclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
[PMID: 18707089] |
| HEL | EC50 |
1.5 μg/mL
Compound: GCV
|
Antiviral activity against foscarnet-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
Antiviral activity against foscarnet-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
[PMID: 18707089] |
| HEL | EC50 |
4.9 μg/mL
Compound: GCV
|
Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl cytosine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl cytosine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
[PMID: 18707089] |
| HEL | EC50 |
6 μg/mL
Compound: GCV
|
Antiviral activity against HCMV 521 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity
Antiviral activity against HCMV 521 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
[PMID: 18707089] |
| HEL | EC50 |
6.2 μg/mL
Compound: GCV
|
Antiviral activity against HCMV 530 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity
Antiviral activity against HCMV 530 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
[PMID: 18707089] |
| HEL | EC50 |
7.6 μg/mL
Compound: GCV
|
Antiviral activity against ganciclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
Antiviral activity against ganciclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
[PMID: 18707089] |
| HEL | EC50 |
9.1 μg/mL
Compound: GCV
|
Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl adenine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl adenine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
[PMID: 18707089] |
| HEL | EC50 |
9.4 μg/mL
Compound: GCV
|
Antiviral activity against HCMV 6 with U97 mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity
Antiviral activity against HCMV 6 with U97 mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
[PMID: 18707089] |
| HEL | CC50 |
146 μg/mL
Compound: ganciclovir
|
Cytotoxicity against HEL cells assessed as reduction of growth after 3 days
Cytotoxicity against HEL cells assessed as reduction of growth after 3 days
|
[PMID: 18835175] |
| HEL | EC50 |
0.51 μg/mL
Compound: ganciclovir
|
Antiviral activity against human cytomegalovirus AD169 in HEL cells assessed as inhibition of viral cytopathicity
Antiviral activity against human cytomegalovirus AD169 in HEL cells assessed as inhibition of viral cytopathicity
|
[PMID: 18835175] |
| HEL | EC50 |
0.8 μg/mL
Compound: ganciclovir
|
Antiviral activity against human cytomegalovirus Davis in HEL cells assessed as inhibition of viral cytopathicity
Antiviral activity against human cytomegalovirus Davis in HEL cells assessed as inhibition of viral cytopathicity
|
[PMID: 18835175] |
| HEL | EC50 |
>100 μg/mL
Compound: Ganciclovir
|
Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
|
[PMID: 18851889] |
| HEL | EC50 |
>100 μg/mL
Compound: Ganciclovir
|
Antiviral activity against VSV infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
Antiviral activity against VSV infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
|
[PMID: 18851889] |
| HEL | EC50 |
0.06 μg/mL
Compound: Ganciclovir
|
Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
|
[PMID: 18851889] |
| HEL | EC50 |
0.06 μg/mL
Compound: Ganciclovir
|
Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
|
[PMID: 18851889] |
| HEL | EC50 |
1 μg/mL
Compound: Ganciclovir
|
Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
|
[PMID: 18851889] |
| HEL | CC50 |
134 μM
Compound: GCV, ganciclovir
|
Cytotoxicity against human HEL cells assessed as reduction of growth after 3 days
Cytotoxicity against human HEL cells assessed as reduction of growth after 3 days
|
[PMID: 19226140] |
| HEL | EC50 |
0.66 μM
Compound: GCV, ganciclovir
|
Antiviral activity against wild type HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against wild type HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathicity
|
[PMID: 19226140] |
| HEL | EC50 |
0.69 μM
Compound: GCV, ganciclovir
|
Antiviral activity against acyclovir-resistant HCMV AD169 clone 1 infected in HEL cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against acyclovir-resistant HCMV AD169 clone 1 infected in HEL cells assessed as inhibition of virus-induced cytopathicity
|
[PMID: 19226140] |
| HEL | EC50 |
0.7 μM
Compound: GCV, ganciclovir
|
Antiviral activity against wild type HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against wild type HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity
|
[PMID: 19226140] |
| HEL | EC50 |
1.2 μM
Compound: GCV, ganciclovir
|
Antiviral activity against HPMPA-resistant HCMV AD169 clone 2 mutant infected in HEL cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against HPMPA-resistant HCMV AD169 clone 2 mutant infected in HEL cells assessed as inhibition of virus-induced cytopathicity
|
[PMID: 19226140] |
| HEL | EC50 |
2 μM
Compound: GCV, ganciclovir
|
Antiviral activity against HCMV AD169 infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection
Antiviral activity against HCMV AD169 infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection
|
[PMID: 19226140] |
| HEL | EC50 |
2.6 μM
Compound: GCV, ganciclovir
|
Antiviral activity against foscarnet-resistant HCMV AD169 clone C infected in HEL cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against foscarnet-resistant HCMV AD169 clone C infected in HEL cells assessed as inhibition of virus-induced cytopathicity
|
[PMID: 19226140] |
| HEL | EC50 |
3.5 μM
Compound: GCV, ganciclovir
|
Antiviral activity against PMEDAP-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against PMEDAP-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity
|
[PMID: 19226140] |
| HEL | EC50 |
3.6 μM
Compound: GCV, ganciclovir
|
Antiviral activity against HCMV Davis infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection
Antiviral activity against HCMV Davis infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection
|
[PMID: 19226140] |
| HEL | EC50 |
4 μM
Compound: GCV, ganciclovir
|
Antiviral activity against cidofovir HCMV AD169 clone 5 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against cidofovir HCMV AD169 clone 5 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity
|
[PMID: 19226140] |
| HEL | EC50 |
4.3 μM
Compound: GCV, ganciclovir
|
Antiviral activity against ganciclovir-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity
Antiviral activity against ganciclovir-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity
|
[PMID: 19226140] |
| HEL | EC50 |
>100 μM
Compound: GCV
|
Antiviral activity against Vaccinia virus Lederle in human HEL cells assessed as protection against virus-induced cytopathicity
Antiviral activity against Vaccinia virus Lederle in human HEL cells assessed as protection against virus-induced cytopathicity
|
[PMID: 19281225] |
| HEL | EC50 |
>100 μM
Compound: GCV
|
Antiviral activity against VSV in human HEL cells assessed as protection against virus-induced cytopathicity
Antiviral activity against VSV in human HEL cells assessed as protection against virus-induced cytopathicity
|
[PMID: 19281225] |
| HEL | EC50 |
0.02 μM
Compound: GCV
|
Antiviral activity against HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity
Antiviral activity against HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity
|
[PMID: 19281225] |
| HEL | EC50 |
0.2 μM
Compound: GCV
|
Antiviral activity against HSV2 G in human HEL cells assessed as protection against virus-induced cytopathicity
Antiviral activity against HSV2 G in human HEL cells assessed as protection against virus-induced cytopathicity
|
[PMID: 19281225] |
| HEL | EC50 |
9 μM
Compound: GCV
|
Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity
Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity
|
[PMID: 19281225] |
| HEL | CC50 |
400 μg/mL
Compound: Ganciclovir
|
Cytotoxicity against Cytomegalovirus infected HEL cells assessed as change in cell morphology
Cytotoxicity against Cytomegalovirus infected HEL cells assessed as change in cell morphology
|
[PMID: 19324473] |
| HEL | CC50 |
80 μg/mL
Compound: Ganciclovir
|
Cytotoxicity against Cytomegalovirus infected HEL cells assessed as reduction in cell growth
Cytotoxicity against Cytomegalovirus infected HEL cells assessed as reduction in cell growth
|
[PMID: 19324473] |
| HEL | EC50 |
1 μg/mL
Compound: Ganciclovir
|
Antiviral activity against Varicella Zoster Virus OKA infected in HEL cells assessed as reduction in virus plaque formation
Antiviral activity against Varicella Zoster Virus OKA infected in HEL cells assessed as reduction in virus plaque formation
|
[PMID: 19324473] |
| HEL | EC50 |
1.4 μg/mL
Compound: Ganciclovir
|
Antiviral activity against Cytomegalovirus AD169 infected in HEL cells assessed as reduction in virus plaque formation
Antiviral activity against Cytomegalovirus AD169 infected in HEL cells assessed as reduction in virus plaque formation
|
[PMID: 19324473] |
| HEL | EC50 |
1.7 μg/mL
Compound: Ganciclovir
|
Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction in virus plaque formation
Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction in virus plaque formation
|
[PMID: 19324473] |
| HEL | EC50 |
15 μg/mL
Compound: Ganciclovir
|
Antiviral activity against thymidine kinase deficient Varicella Zoster Virus 07/1 infected in HEL cells assessed as reduction in virus plaque formation
Antiviral activity against thymidine kinase deficient Varicella Zoster Virus 07/1 infected in HEL cells assessed as reduction in virus plaque formation
|
[PMID: 19324473] |
| HEL | CC50 |
221 μM
Compound: 1b, GCV
|
Cytotoxicity against human HEL cells assessed as reduction in cell growth after 3 days
Cytotoxicity against human HEL cells assessed as reduction in cell growth after 3 days
|
[PMID: 19339082] |
| HEL | EC50 |
0.59 μM
Compound: 1b, GCV
|
Antiviral activity against Varicella zoster virus OKA infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days
Antiviral activity against Varicella zoster virus OKA infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days
|
[PMID: 19339082] |
| HEL | EC50 |
1.1 μM
Compound: 1b, GCV
|
Antiviral activity against Varicella zoster virus YS infected in human HEL cells assessed as inhibition of virus induced cytopathicity after 5 days
Antiviral activity against Varicella zoster virus YS infected in human HEL cells assessed as inhibition of virus induced cytopathicity after 5 days
|
[PMID: 19339082] |
| HEL | EC50 |
12.6 μM
Compound: 1b, GCV
|
Antiviral activity against human cytomegalovirus AD169 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection
Antiviral activity against human cytomegalovirus AD169 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection
|
[PMID: 19339082] |
| HEL | EC50 |
2.5 μM
Compound: 1b, GCV
|
Antiviral activity against human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection
Antiviral activity against human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection
|
[PMID: 19339082] |
| HEL | EC50 |
2.5 μM
Compound: 1b, GCV
|
Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days
Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days
|
[PMID: 19339082] |
| HEL | EC50 |
>100 μg/mL
Compound: ganciclovir
|
Antiviral activity against Vaccinia virus infected in in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
Antiviral activity against Vaccinia virus infected in in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
|
[PMID: 19419804] |
| HEL | EC50 |
>100 μg/mL
Compound: ganciclovir
|
Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
|
[PMID: 19419804] |
| HEL | EC50 |
0.08 μg/mL
Compound: ganciclovir
|
Antiviral activity against HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
Antiviral activity against HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
|
[PMID: 19419804] |
| HEL | EC50 |
0.08 μg/mL
Compound: ganciclovir
|
Antiviral activity against HSV2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
Antiviral activity against HSV2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
|
[PMID: 19419804] |
| HEL | EC50 |
6 μg/mL
Compound: ganciclovir
|
Antiviral activity against thymidine kinase-deficient ACV-resistant HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
Antiviral activity against thymidine kinase-deficient ACV-resistant HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
|
[PMID: 19419804] |
| HEL | CC50 |
>100 μM
Compound: Ganciclovir
|
Cytotoxicity against acyclovir-sensitive Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method
Cytotoxicity against acyclovir-sensitive Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method
|
[PMID: 20034711] |
| HEL | CC50 |
>100 μM
Compound: Ganciclovir
|
Cytotoxicity against Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method
Cytotoxicity against Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method
|
[PMID: 20034711] |
| HEL | CC50 |
>100 μM
Compound: Ganciclovir
|
Cytotoxicity against Herpes simplex virus 2 G infected HEL cells by trypan blue exclusion method
Cytotoxicity against Herpes simplex virus 2 G infected HEL cells by trypan blue exclusion method
|
[PMID: 20034711] |
| HEL | CC50 |
>100 μM
Compound: Ganciclovir
|
Cytotoxicity against Vaccinia virus infected HEL cells by trypan blue exclusion method
Cytotoxicity against Vaccinia virus infected HEL cells by trypan blue exclusion method
|
[PMID: 20034711] |
| HEL | CC50 |
>100 μM
Compound: Ganciclovir
|
Cytotoxicity against VSV infected HEL cells by trypan blue exclusion method
Cytotoxicity against VSV infected HEL cells by trypan blue exclusion method
|
[PMID: 20034711] |
| HEL | EC50 |
>100 μM
Compound: Ganciclovir
|
Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay
Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay
|
[PMID: 20034711] |
| HEL | EC50 |
>100 μM
Compound: Ganciclovir
|
Antiviral activity against VSV infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 1 to 2 days by MTT assay
Antiviral activity against VSV infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 1 to 2 days by MTT assay
|
[PMID: 20034711] |
| HEL | EC50 |
0.03 μM
Compound: Ganciclovir
|
Antiviral activity against acyclovir-sensitive Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay
Antiviral activity against acyclovir-sensitive Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay
|
[PMID: 20034711] |
| HEL | EC50 |
0.03 μM
Compound: Ganciclovir
|
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay
|
[PMID: 20034711] |
| HEL | EC50 |
0.03 μM
Compound: Ganciclovir
|
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay
|
[PMID: 20034711] |
| HEL | EC50 |
>100 μg/mL
Compound: Ganciclovir
|
Antiviral activity against Vaccinia virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
Antiviral activity against Vaccinia virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
|
[PMID: 20724039] |
| HEL | EC50 |
>100 μg/mL
Compound: Ganciclovir
|
Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
|
[PMID: 20724039] |
| HEL | EC50 |
0.05 μg/mL
Compound: Ganciclovir
|
Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
|
[PMID: 20724039] |
| HEL | EC50 |
0.07 μg/mL
Compound: Ganciclovir
|
Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
|
[PMID: 20724039] |
| HEL | EC50 |
2 μg/mL
Compound: Ganciclovir
|
Antiviral activity against acyclovir-resistant TK deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
Antiviral activity against acyclovir-resistant TK deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
|
[PMID: 20724039] |
| HEL | CC50 |
1077 μM
Compound: Ganciclovir
|
Cytotoxicity against HEL
Cytotoxicity against HEL
|
[PMID: 20809641] |
| HEL | EC50 |
>100 μg/mL
Compound: Ganciclovir
|
Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
|
[PMID: 20971531] |
| HEL | EC50 |
>100 μg/mL
Compound: Ganciclovir
|
Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
|
[PMID: 20971531] |
| HEL | EC50 |
0.03 μg/mL
Compound: Ganciclovir
|
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
|
[PMID: 20971531] |
| HEL | EC50 |
0.03 μg/mL
Compound: Ganciclovir
|
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
|
[PMID: 20971531] |
| HEL | EC50 |
58 μg/mL
Compound: Ganciclovir
|
Antiviral activity against thymidine kinase deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
Antiviral activity against thymidine kinase deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
|
[PMID: 20971531] |
| HEL | CC50 |
164 μM
Compound: Ganciclovir
|
Cytotoxicity against human HEL cells after 3 days
Cytotoxicity against human HEL cells after 3 days
|
[PMID: 21128666] |
| HEL | EC50 |
>100 μM
Compound: Ganciclovir
|
Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days
Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days
|
[PMID: 21128666] |
| HEL | EC50 |
0.05 μM
Compound: Ganciclovir
|
Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days
Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days
|
[PMID: 21128666] |
| HEL | EC50 |
0.08 μM
Compound: Ganciclovir
|
Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days
Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days
|
[PMID: 21128666] |
| HEL | EC50 |
3 μM
Compound: Ganciclovir
|
Antiviral activity against acyclovir-resistant thymidine kinase deficient HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days
Antiviral activity against acyclovir-resistant thymidine kinase deficient HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days
|
[PMID: 21128666] |
| HEL | EC50 |
5.2 μM
Compound: Ganciclovir
|
Antiviral activity against HCMV AD169/Davis infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days
Antiviral activity against HCMV AD169/Davis infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days
|
[PMID: 21128666] |
| HEL | CC50 |
>250 μM
Compound: Ganciclovir
|
Cytotoxicity against HEL cells after 3 days by coulter counter analysis
Cytotoxicity against HEL cells after 3 days by coulter counter analysis
|
[PMID: 21232828] |
| HEL | EC50 |
>100 μM
Compound: Ganciclovir
|
Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
|
[PMID: 21232828] |
| HEL | EC50 |
0.01 μM
Compound: Ganciclovir
|
Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
|
[PMID: 21232828] |
| HEL | EC50 |
0.04 μM
Compound: Ganciclovir
|
Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
|
[PMID: 21232828] |
| HEL | EC50 |
0.1 μM
Compound: Ganciclovir
|
Antiviral activity against thymidine kinase deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
Antiviral activity against thymidine kinase deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
|
[PMID: 21232828] |
| HEL | CC50 |
435 μM
Compound: Ganciclovir
|
Cytotoxicity against human HEL cells assessed as growth inhibition after 3 days by coulter counter
Cytotoxicity against human HEL cells assessed as growth inhibition after 3 days by coulter counter
|
[PMID: 21565516] |
| HEL | EC50 |
>250 μM
Compound: Ganciclovir
|
Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection against virus-induced cytopathicity
Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection against virus-induced cytopathicity
|
[PMID: 21565516] |
| HEL | EC50 |
0.027 μM
Compound: Ganciclovir
|
Antiviral activity against Human herpesvirus 2 G infected in HEL cells assessed as protection against virus-induced cytopathicity
Antiviral activity against Human herpesvirus 2 G infected in HEL cells assessed as protection against virus-induced cytopathicity
|
[PMID: 21565516] |
| HEL | EC50 |
0.03 μM
Compound: Ganciclovir
|
Antiviral activity against Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity
Antiviral activity against Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity
|
[PMID: 21565516] |
| HEL | EC50 |
15.7 μM
Compound: Ganciclovir
|
Antiviral activity against acyclovir-resistant Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity
Antiviral activity against acyclovir-resistant Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity
|
[PMID: 21565516] |
| HEL | EC50 |
6 μM
Compound: Ganciclovir
|
Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as protection against virus-induced cytopathicity
Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as protection against virus-induced cytopathicity
|
[PMID: 21565516] |
| HEL | EC50 |
6.54 μM
Compound: Ganciclovir
|
Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as protection against virus-induced cytopathicity
Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as protection against virus-induced cytopathicity
|
[PMID: 21565516] |
| HEL | EC50 |
>100 μM
Compound: Ganciclovir
|
Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis
Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis
|
[PMID: 21696963] |
| HEL | EC50 |
0.03 μM
Compound: Ganciclovir
|
Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis
Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis
|
[PMID: 21696963] |
| HEL | EC50 |
0.03 μM
Compound: Ganciclovir
|
Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis
Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis
|
[PMID: 21696963] |
| HEL | EC50 |
0.8 μM
Compound: Ganciclovir
|
Antiviral activity against acyclovir-resistant TK-deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis
Antiviral activity against acyclovir-resistant TK-deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis
|
[PMID: 21696963] |
| HEL | CC50 |
543 μM
Compound: Ganciclovir
|
Cytotoxicity against human HEL cells after 3 days by coulter counter
Cytotoxicity against human HEL cells after 3 days by coulter counter
|
[PMID: 21745746] |
| HEL | EC50 |
>100 μM
Compound: Ganciclovir
|
Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
|
[PMID: 22459876] |
| HEL | EC50 |
>100 μM
Compound: Ganciclovir
|
Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
|
[PMID: 22459876] |
| HEL | EC50 |
0.02 μM
Compound: Ganciclovir
|
Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
|
[PMID: 22459876] |
| HEL | EC50 |
0.03 μM
Compound: Ganciclovir
|
Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
|
[PMID: 22459876] |
| HEL | EC50 |
1.65 μM
Compound: Ganciclovir
|
Antiviral activity against Cytomegalovirus AD-169 infected in HEL cells assessed as inhibition of virus plaque formation after 4 days
Antiviral activity against Cytomegalovirus AD-169 infected in HEL cells assessed as inhibition of virus plaque formation after 4 days
|
[PMID: 22459876] |
| HEL | EC50 |
1.65 μM
Compound: Ganciclovir
|
Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus plaque formation after 4 days
Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus plaque formation after 4 days
|
[PMID: 22459876] |
| HEL | EC50 |
100 μM
Compound: Ganciclovir
|
Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
|
[PMID: 22459876] |
| HEL | CC50 |
130 μM
Compound: Ganciclovir
|
Cytostatic against human HEL cells assessed as reduction in cell growth after 3 days by coulter counter
Cytostatic against human HEL cells assessed as reduction in cell growth after 3 days by coulter counter
|
[PMID: 22578783] |
| HEL | EC50 |
7.1 μM
Compound: Ganciclovir
|
Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as reduction in virus-induced cytopathicity
Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as reduction in virus-induced cytopathicity
|
[PMID: 22578783] |
| HEL | EC50 |
7.5 μM
Compound: Ganciclovir
|
Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as reduction in virus-induced cytopathicity
Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as reduction in virus-induced cytopathicity
|
[PMID: 22578783] |
| HEL | CC50 |
231 μM
Compound: Ganciclovir
|
Cytotoxicity against HEL cells assessed as effect on cell growth incubated for 3 days by Coulter counter assay
Cytotoxicity against HEL cells assessed as effect on cell growth incubated for 3 days by Coulter counter assay
|
[PMID: 22858222] |
| HEL | EC50 |
0.027 μM
Compound: Ganciclovir
|
Antiviral activity against HSV1 KOS infected in HEL cells by viral CPE assay
Antiviral activity against HSV1 KOS infected in HEL cells by viral CPE assay
|
[PMID: 22858222] |
| HEL | EC50 |
0.029 μM
Compound: Ganciclovir
|
Antiviral activity against HSV2 G infected in HEL cells by viral CPE assay
Antiviral activity against HSV2 G infected in HEL cells by viral CPE assay
|
[PMID: 22858222] |
| HEL | EC50 |
14.7 μM
Compound: Ganciclovir
|
Antiviral activity against thymidine kinase negative and ACV resistant HSV1 KOS infected in HEL cells by viral CPE assay
Antiviral activity against thymidine kinase negative and ACV resistant HSV1 KOS infected in HEL cells by viral CPE assay
|
[PMID: 22858222] |
| HEL | EC50 |
5.9 μM
Compound: Ganciclovir
|
Antiviral activity against HCMV Davis infected in HEL cells by viral CPE assay
Antiviral activity against HCMV Davis infected in HEL cells by viral CPE assay
|
[PMID: 22858222] |
| HEL | EC50 |
9.1 μM
Compound: Ganciclovir
|
Antiviral activity against HCMV AD169 infected in HEL cells by viral CPE assay
Antiviral activity against HCMV AD169 infected in HEL cells by viral CPE assay
|
[PMID: 22858222] |
| HEL | EC50 |
≥93 μM
Compound: Ganciclovir
|
Antiviral activity against Vaccinia virus Lederie infected in HEL cells by viral CPE assay
Antiviral activity against Vaccinia virus Lederie infected in HEL cells by viral CPE assay
|
[PMID: 22858222] |
| HEL | EC50 |
>100 μM
Compound: Ganciclovir
|
Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
|
[PMID: 23099097] |
| HEL | EC50 |
>100 μM
Compound: Ganciclovir
|
Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
|
[PMID: 23099097] |
| HEL | EC50 |
0.013 μM
Compound: Ganciclovir
|
Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
|
[PMID: 23099097] |
| HEL | EC50 |
0.015 μM
Compound: Ganciclovir
|
Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
|
[PMID: 23099097] |
| HEL | EC50 |
4 μM
Compound: Ganciclovir
|
Antiviral activity against thymidine kinase deficient and acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
Antiviral activity against thymidine kinase deficient and acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
|
[PMID: 23099097] |
| HEL | CC50 |
200 μM
Compound: Ganciclovir
|
Cytotoxicity against HEL
Cytotoxicity against HEL
|
[PMID: 23743443] |
| HEL | EC50 |
0.01 μM
Compound: ganciclovir
|
Antiviral activity against HSV-1 KOS infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity
Antiviral activity against HSV-1 KOS infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity
|
[PMID: 23795238] |
| HEL | EC50 |
0.01 μM
Compound: ganciclovir
|
Antiviral activity against HSV-2 G infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity
Antiviral activity against HSV-2 G infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity
|
[PMID: 23795238] |
| HEL | EC50 |
1 μM
Compound: ganciclovir
|
Antiviral activity against ACV-resistant TK-deficient HSV-1 KOS infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity
Antiviral activity against ACV-resistant TK-deficient HSV-1 KOS infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity
|
[PMID: 23795238] |
| HEL | EC50 |
100 μM
Compound: ganciclovir
|
Antiviral activity against Vaccinia virus Lederle infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity
Antiviral activity against Vaccinia virus Lederle infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity
|
[PMID: 23795238] |
| HEL | EC50 |
>100 μM
Compound: Ganciclovir
|
Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity
Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity
|
[PMID: 23811093] |
| HEL | EC50 |
>100 μM
Compound: Ganciclovir
|
Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity
Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity
|
[PMID: 23811093] |
| HEL | EC50 |
0.03 μM
Compound: Ganciclovir
|
Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity
Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity
|
[PMID: 23811093] |
| HEL | EC50 |
0.03 μM
Compound: Ganciclovir
|
Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity
Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity
|
[PMID: 23811093] |
| HEL | EC50 |
4 μM
Compound: Ganciclovir
|
Antiviral activity against TK-negative Herpes simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity
Antiviral activity against TK-negative Herpes simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity
|
[PMID: 23811093] |
| HEL | EC50 |
5.98 μM
Compound: Ganciclovir
|
Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction of plaque formation
Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction of plaque formation
|
[PMID: 23811093] |
| HEL | EC50 |
7.87 μM
Compound: Ganciclovir
|
Antiviral activity against Cytomegalovirus AD-169 infected in human HEL cells assessed as reduction of plaque formation
Antiviral activity against Cytomegalovirus AD-169 infected in human HEL cells assessed as reduction of plaque formation
|
[PMID: 23811093] |
| HEL | CC50 |
>350 μM
Compound: Ganciclovir
|
Cytotoxicity against human HEL cells after 3 days by Coulter counting method
Cytotoxicity against human HEL cells after 3 days by Coulter counting method
|
[PMID: 23911854] |
| HEL | EC50 |
8.2 μM
Compound: Ganciclovir
|
Antiviral activity against human Cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity after
Antiviral activity against human Cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity after
|
[PMID: 23911854] |
| HEL | EC50 |
>100 μM
Compound: Ganciclovir
|
Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity
Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity
|
[PMID: 23911856] |
| HEL | EC50 |
0.38 μM
Compound: Ganciclovir
|
Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus plaque formation
Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus plaque formation
|
[PMID: 23911856] |
| HEL | EC50 |
0.9 μM
Compound: Ganciclovir
|
Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity
Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity
|
[PMID: 23911856] |
| HEL | EC50 |
3.1 μM
Compound: Ganciclovir
|
Antiviral activity against Cytomegalovirus AD-169 infected in human HEL cells assessed as reduction in virus plaque formation
Antiviral activity against Cytomegalovirus AD-169 infected in human HEL cells assessed as reduction in virus plaque formation
|
[PMID: 23911856] |
| HEL | EC50 |
>100 μM
Compound: Ganciclovir
|
Antiviral activity against Vaccinia virus infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
Antiviral activity against Vaccinia virus infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
[PMID: 26001344] |
| HEL | EC50 |
0.02 μM
Compound: Ganciclovir
|
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
[PMID: 26001344] |
| HEL | EC50 |
0.03 μM
Compound: Ganciclovir
|
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
[PMID: 26001344] |
| HEL | EC50 |
0.5 μM
Compound: Ganciclovir
|
Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
[PMID: 26001344] |
| HEL | EC50 |
6.3 μM
Compound: Ganciclovir
|
Antiviral activity against Cytomegalovirus AD-169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
Antiviral activity against Cytomegalovirus AD-169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
[PMID: 26001344] |
| HEL | EC50 |
7.1 μM
Compound: Ganciclovir
|
Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
|
[PMID: 26001344] |
| HEL | CC50 |
328.5 μM
Compound: Ganciclovir
|
Cytotoxicity against human HEL cells assessed as cell growth reduction incubated for 3 days
Cytotoxicity against human HEL cells assessed as cell growth reduction incubated for 3 days
|
[PMID: 26291038] |
| HEL | EC50 |
4.72 μM
Compound: Ganciclovir
|
Antiviral activity against Human cytomegalovirus Davis expressed in HEL cells assessed as reduction in plaque formation incubated for 7 days by Giemsa stain based microscopy
Antiviral activity against Human cytomegalovirus Davis expressed in HEL cells assessed as reduction in plaque formation incubated for 7 days by Giemsa stain based microscopy
|
[PMID: 26291038] |
| HEL | EC50 |
6.12 μM
Compound: Ganciclovir
|
Antiviral activity against Human cytomegalovirus AD169 expressed in HEL cells assessed as reduction in plaque formation incubated for 7 days by Giemsa stain based microscopy
Antiviral activity against Human cytomegalovirus AD169 expressed in HEL cells assessed as reduction in plaque formation incubated for 7 days by Giemsa stain based microscopy
|
[PMID: 26291038] |
| HEL | EC50 |
13.9 μM
Compound: GCV
|
Antiviral activity against human cytomegalovirus AD169 infected in HEL cells assessed as reduction in viral plaque formation
Antiviral activity against human cytomegalovirus AD169 infected in HEL cells assessed as reduction in viral plaque formation
|
[PMID: 26443550] |
| HEL | EC50 |
7.8 μM
Compound: GCV
|
Antiviral activity against human cytomegalovirus Davis infected in HEL cells assessed as reduction in viral plaque formation
Antiviral activity against human cytomegalovirus Davis infected in HEL cells assessed as reduction in viral plaque formation
|
[PMID: 26443550] |
| HEL | CC50 |
≥319 μM
Compound: GCV
|
Cytotoxicity against human cytomegalovirus infected HEL cells assessed as cell growth inhibition incubated for 3 days by coulter counter method
Cytotoxicity against human cytomegalovirus infected HEL cells assessed as cell growth inhibition incubated for 3 days by coulter counter method
|
[PMID: 26443550] |
| HEL | EC50 |
0.25 μM
Compound: Ganciclovir
|
Antiviral activity against Cytomegalovirus AD169 infected in HEL cells
Antiviral activity against Cytomegalovirus AD169 infected in HEL cells
|
[PMID: 27128178] |
| HEL | EC50 |
0.4 μM
Compound: Ganciclovir
|
Antiviral activity against Cytomegalovirus Davis 07/1 infected in HEL cells
Antiviral activity against Cytomegalovirus Davis 07/1 infected in HEL cells
|
[PMID: 27128178] |
| HEL | EC50 |
0.03 μM
Compound: Ganciclovir
|
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus plaque formation
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus plaque formation
|
[PMID: 27639368] |
| HEL | EC50 |
0.09 μM
Compound: Ganciclovir
|
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation
|
[PMID: 27639368] |
| HEL | EC50 |
100 μM
Compound: Ganciclovir
|
Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation
Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation
|
[PMID: 27639368] |
| HEL | EC50 |
2.1 μM
Compound: Ganciclovir
|
Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus plaque formation
Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus plaque formation
|
[PMID: 27639368] |
| HEL | EC50 |
3.1 μM
Compound: Ganciclovir
|
Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus plaque formation
Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus plaque formation
|
[PMID: 27639368] |
| HEL | CC50 |
>350 μM
Compound: Ganciclovir
|
Cytotoxicity against HEL cells infected with Cytomegalovirus assessed as growth inhibition
Cytotoxicity against HEL cells infected with Cytomegalovirus assessed as growth inhibition
|
[PMID: 27750154] |
| HEL | CC50 |
>391 μM
Compound: Ganciclovir
|
Cytotoxic activity against HEL cells assessed as reduction in cell proliferation after 3 days by coulter counting method
Cytotoxic activity against HEL cells assessed as reduction in cell proliferation after 3 days by coulter counting method
|
[PMID: 28682067] |
| HEL | CC50 |
308 μM
Compound: Ganciclovir
|
Cytotoxicity against HEL cells assessed as reduction in cell growth after 3 days by coulter counter method
Cytotoxicity against HEL cells assessed as reduction in cell growth after 3 days by coulter counter method
|
[PMID: 28757102] |
| HEL | CC50 |
273 μM
Compound: 1
|
Cytotoxicity against human HEL cells assessed as cell growth inhibition by cell counting method
Cytotoxicity against human HEL cells assessed as cell growth inhibition by cell counting method
|
[PMID: 28829913] |
| HEL | CC50 |
>350 μM
Compound: Ganciclovir
|
Cytostatic activity against HEL cells after 3 days by Coulter counting method
Cytostatic activity against HEL cells after 3 days by Coulter counting method
|
[PMID: 29407990] |
| HEL | CC50 |
>391 μM
Compound: Ganciclovir
|
Cytostatic activity against HEL cells after 3 days by Coulter counting method
Cytostatic activity against HEL cells after 3 days by Coulter counting method
|
[PMID: 29550734] |
| HEL | CC50 |
>319 μM
Compound: Ganciclovir
|
Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method
Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method
|
[PMID: 29670705] |
| HEL | EC50 |
>100 μM
Compound: Ganciclovir
|
Antiviral activity against Vaccinia virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
Antiviral activity against Vaccinia virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
|
[PMID: 32214762] |
| HEL | EC50 |
>100 μM
Compound: Ganciclovir
|
Antiviral activity against Vesicular stomatitis virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
Antiviral activity against Vesicular stomatitis virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
|
[PMID: 32214762] |
| HEL | EC50 |
0.07 μM
Compound: Ganciclovir
|
Antiviral activity against Human herpesvirus 2 strain G infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
Antiviral activity against Human herpesvirus 2 strain G infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
|
[PMID: 32214762] |
| HEL | EC50 |
0.09 μM
Compound: Ganciclovir
|
Antiviral activity against Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
Antiviral activity against Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
|
[PMID: 32214762] |
| HEL | EC50 |
≥20 μM
Compound: Ganciclovir
|
Antiviral activity against acyclovir-resistant thymidine kinase negative Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
Antiviral activity against acyclovir-resistant thymidine kinase negative Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
|
[PMID: 32214762] |
| HEL | CC50 |
>394 μM
Compound: Ganciclovir
|
Cytotoxicity against human HEL cells assessed as reduction in cell proliferation incubated for 3 days by Coulter counter method
Cytotoxicity against human HEL cells assessed as reduction in cell proliferation incubated for 3 days by Coulter counter method
|
[PMID: 32676147] |
| HEL | EC50 |
13 μM
Compound: Ganciclovir
|
Antiviral activity against Cytomegalovirus AD169 infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity measured after 6 to 7 days
Antiviral activity against Cytomegalovirus AD169 infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity measured after 6 to 7 days
|
[PMID: 32676147] |
| HEL | EC50 |
4.44 μM
Compound: Ganciclovir
|
Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity measured after 6 to 7 days
Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity measured after 6 to 7 days
|
[PMID: 32676147] |
| HEL | CC50 |
231.22 μM
Compound: Ganciclovir
|
Cytotoxicity against human HEL cells assessed as reduce in cell growth incubated for 3 days by coulter counter analysis
Cytotoxicity against human HEL cells assessed as reduce in cell growth incubated for 3 days by coulter counter analysis
|
[PMID: 33479570] |
| HEL | CC50 |
>300 μM
Compound: Ganciclovir
|
Cytotoxicity against human HEL cells assessed as reduction in cell viability measured after 3 days by beckman coulter counting method
Cytotoxicity against human HEL cells assessed as reduction in cell viability measured after 3 days by beckman coulter counting method
|
[PMID: 33894564] |
| HEL | CC50 |
130 μM
Compound: Ganciclovir
|
Cytostatic activity against human HEL cells assessed as reduction in cell growth measured after 24 hrs
Cytostatic activity against human HEL cells assessed as reduction in cell growth measured after 24 hrs
|
[PMID: 38643669] |
| HEL | IC50 |
0.5 μM
Compound: ganciclovir
|
Inhibition of human CMV DNA synthesis in CMV-infected HEL cells.
Inhibition of human CMV DNA synthesis in CMV-infected HEL cells.
|
[PMID: 7752205] |
| HEL | IC50 |
7 μM
Compound: ganciclovir
|
Inhibition against DNA of uninfected HEL cells by incorporation of [3H]TdR.
Inhibition against DNA of uninfected HEL cells by incorporation of [3H]TdR.
|
[PMID: 7752205] |
| HEL | CC50 |
>200 μg/mL
Compound: GCV
|
Tested for the cytotoxic concentration, required to reduce cell growth by 50% in human embryonic lung (HEL) cells.
Tested for the cytotoxic concentration, required to reduce cell growth by 50% in human embryonic lung (HEL) cells.
|
[PMID: 7877148] |
| HEL | IC50 |
0.02 μg/mL
Compound: GCV
|
Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain OKA plaque formation by 50%.
Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain OKA plaque formation by 50%.
|
[PMID: 7877148] |
| HEL | IC50 |
0.072 μg/mL
Compound: GCV
|
Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain YS plaque formation by 50%
Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain YS plaque formation by 50%
|
[PMID: 7877148] |
| HEL | IC50 |
0.1 μg/mL
Compound: GCV
|
Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain 07/1 plaque formation by 50%.
Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain 07/1 plaque formation by 50%.
|
[PMID: 7877148] |
| HEL | IC50 |
0.9 μg/mL
Compound: GCV
|
Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain YS/R plaque formation by 50%.
Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain YS/R plaque formation by 50%.
|
[PMID: 7877148] |
| HEL | IC50 |
2.9 μg/mL
Compound: GCV
|
Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain AD-169 plaque formation by 50%.
Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain AD-169 plaque formation by 50%.
|
[PMID: 7877148] |
| HEL | IC50 |
6.2 μg/mL
Compound: GCV
|
Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain Davis plaque formation by 50%.
Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain Davis plaque formation by 50%.
|
[PMID: 7877148] |
| HEL | ED50 |
0.016 μg/mL
Compound: DHPG
|
Antiviral activity against herpes simplex virus-1 VR-3 strain in HEL (human erythroleukemia) cells.
Antiviral activity against herpes simplex virus-1 VR-3 strain in HEL (human erythroleukemia) cells.
|
[PMID: 9216836] |
| HEL | ED50 |
0.039 μg/mL
Compound: DHPG
|
Antiviral activity against herpes simplex virus-2 (HSV-2) Ms strain in HEL (human erythroleukemia) cells.
Antiviral activity against herpes simplex virus-2 (HSV-2) Ms strain in HEL (human erythroleukemia) cells.
|
[PMID: 9216836] |
| HEL | ED50 |
0.21 μg/mL
Compound: DHPG
|
Antiviral activity against human cytomegalovirus (HCMV) AD 169 strain HEL (human erythroleukemia) cells.
Antiviral activity against human cytomegalovirus (HCMV) AD 169 strain HEL (human erythroleukemia) cells.
|
[PMID: 9216836] |
| HEL | ED50 |
0.21 μg/mL
Compound: DHPG
|
Antiviral activity against varicella zoster virus (VZV) Oka strain in HEL (human erythroleukemia) cells.
Antiviral activity against varicella zoster virus (VZV) Oka strain in HEL (human erythroleukemia) cells.
|
[PMID: 9216836] |
| HEL | IC50 |
0.5 μg/mL
Compound: ganciclovir
|
Anti CMV (Cytomegalovirus- virus) activity against AD-169 strain in HEL cells
Anti CMV (Cytomegalovirus- virus) activity against AD-169 strain in HEL cells
|
[PMID: 9836626] |
| HEL | IC50 |
0.5 μg/mL
Compound: ganciclovir
|
Anti CMV (Cytomegalovirus- virus) activity against Davis strain in HEL cells
Anti CMV (Cytomegalovirus- virus) activity against Davis strain in HEL cells
|
[PMID: 9836626] |
| HEL | EC50 |
>100 μM
Compound: Ganciclovir
|
Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
|
10.1007/s00044-009-9248-y |
| HEL | EC50 |
>100 μM
Compound: Ganciclovir
|
Antiviral activity against Vesicular stomatitis virus infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
Antiviral activity against Vesicular stomatitis virus infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
|
10.1007/s00044-009-9248-y |
| HEL | EC50 |
0.08 μM
Compound: Ganciclovir
|
Antiviral activity against Human herpesvirus 1 strain KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
Antiviral activity against Human herpesvirus 1 strain KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
|
10.1007/s00044-009-9248-y |
| HEL | EC50 |
0.08 μM
Compound: Ganciclovir
|
Antiviral activity against Human herpesvirus 2 strain G infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
Antiviral activity against Human herpesvirus 2 strain G infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
|
10.1007/s00044-009-9248-y |
| HEL | EC50 |
6 μM
Compound: Ganciclovir
|
Antiviral activity against acyclovir-resistant TK-deficient Hepres simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
Antiviral activity against acyclovir-resistant TK-deficient Hepres simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
|
10.1007/s00044-009-9248-y |
| HEL | CC50 |
60.5 μg/mL
Compound: Ganciclovir
|
Cytotoxicity against HEL
Cytotoxicity against HEL
|
10.1007/s00044-011-9776-0 |
| HEL | EC50 |
1.79 μg/mL
Compound: Ganciclovir
|
Antiviral activity against Human herpesvirus 5 Davis infected human HEL cells assessed as reduction in the virus plaque formation
Antiviral activity against Human herpesvirus 5 Davis infected human HEL cells assessed as reduction in the virus plaque formation
|
10.1007/s00044-011-9776-0 |
| HEL | EC50 |
2.68 μg/mL
Compound: Ganciclovir
|
Antiviral activity against Human herpesvirus 5 strain AD169 infected human HEL cells assessed as reduction in the virus plaque formation
Antiviral activity against Human herpesvirus 5 strain AD169 infected human HEL cells assessed as reduction in the virus plaque formation
|
10.1007/s00044-011-9776-0 |
| HEL | CC50 |
200 μg/mL
Compound: 11) 2 (Ganciclovir GCV)
|
Cytotoxicity (to reduce cell growth) against Cytomegalovirus in human embryonic lung (HEL) cells
Cytotoxicity (to reduce cell growth) against Cytomegalovirus in human embryonic lung (HEL) cells
|
10.1016/S0960-894X(01)80538-2 |
| HEL | IC50 |
1.5 μg/mL
Compound: 11) 2 (Ganciclovir GCV)
|
Antiviral activity against Cytomegalovirus (Davis strain) to reduce plaque formation in human embryonic lung (HEL) cells
Antiviral activity against Cytomegalovirus (Davis strain) to reduce plaque formation in human embryonic lung (HEL) cells
|
10.1016/S0960-894X(01)80538-2 |
| HEL | IC50 |
2 μg/mL
Compound: 11) 2 (Ganciclovir GCV)
|
Antiviral activity against Cytomegalovirus (AD-169 strain) to reduce plaque formation in human embryonic lung (HEL) cells
Antiviral activity against Cytomegalovirus (AD-169 strain) to reduce plaque formation in human embryonic lung (HEL) cells
|
10.1016/S0960-894X(01)80538-2 |
| HEL | IC50 |
1.2 μg/mL
Compound: Ganciclovir
|
Antiviral activity was measured against cytomegalovirus (CMV) AD-169 strain in human embryonic lung (HEL) cells
Antiviral activity was measured against cytomegalovirus (CMV) AD-169 strain in human embryonic lung (HEL) cells
|
10.1016/S0960-894X(97)00149-2 |
| HEL | IC50 |
1.3 μg/mL
Compound: Ganciclovir
|
Antiviral activity was measured against cytomegalovirus (CMV) Davis strain in human embryonic lung (HEL) cells
Antiviral activity was measured against cytomegalovirus (CMV) Davis strain in human embryonic lung (HEL) cells
|
10.1016/S0960-894X(97)00149-2 |
| HEL 299 | CC50 |
>10 μg/mL
Compound: GCV
|
Cytotoxic concentration of compound was tested against HEL299(human embryonic lung fibroblast) cells using cytotoxic assay
Cytotoxic concentration of compound was tested against HEL299(human embryonic lung fibroblast) cells using cytotoxic assay
|
[PMID: 11262090] |
| HEL 299 | CC50 |
>333 μM
Compound: GCV, Ganciclovir
|
Cytotoxicity against HEL299 cells infected with human cytomegalovirus after 7 days by alamar blue assay
Cytotoxicity against HEL299 cells infected with human cytomegalovirus after 7 days by alamar blue assay
|
[PMID: 20047911] |
| HEL 299 | EC50 |
2.39 μM
Compound: GCV, Ganciclovir
|
Antiviral activity against human cytomegalovirus infected in HEL299 cells after 7 days by GFP-based fluorescent reduction assay
Antiviral activity against human cytomegalovirus infected in HEL299 cells after 7 days by GFP-based fluorescent reduction assay
|
[PMID: 20047911] |
| HEL 299 | CC50 |
>100 μM
Compound: 1b
|
Cytotoxicity against human HEL299 cells after 3 days by MTT assay
Cytotoxicity against human HEL299 cells after 3 days by MTT assay
|
[PMID: 26460883] |
| HEL 299 | CC50 |
>50 μM
Compound: GCV
|
Cytotoxicity against human HEL 299 cells assessed as cell death incubated for 168 hrs by MTS-based tetrazolium reduction assay
Cytotoxicity against human HEL 299 cells assessed as cell death incubated for 168 hrs by MTS-based tetrazolium reduction assay
|
[PMID: 34147908] |
| HEL 299 | CC50 |
>100 μM
Compound: ganciclovir
|
In vitro cytotoxicity of the compound (Concentration required to reduce OD value by 50%) in human embryonic lung fibroblast(HEL 299) cells determined by MTT assay.
In vitro cytotoxicity of the compound (Concentration required to reduce OD value by 50%) in human embryonic lung fibroblast(HEL 299) cells determined by MTT assay.
|
[PMID: 9925738] |
| HEL 299 | EC50 |
0.63 μM
Compound: ganciclovir
|
In vitro antiviral (HCMV-AD169) activity of the compound (Concentration required to reduce 50% of the plaques) determined by plaque reduction assay.
In vitro antiviral (HCMV-AD169) activity of the compound (Concentration required to reduce 50% of the plaques) determined by plaque reduction assay.
|
[PMID: 9925738] |
| HEL 299 | CC50 |
>400 μg/mL
Compound: ganciclovir
|
Compound was tested for its cytotoxicity against human embryonic lung fibroblast cells (HEL 299) by MTT dye reduction assay
Compound was tested for its cytotoxicity against human embryonic lung fibroblast cells (HEL 299) by MTT dye reduction assay
|
10.1016/S0960-894X(00)80078-5 |
| HeLa | EC50 |
>100 μM
Compound: Gancyclovir, DHPG
|
Effective concentration required to inhibit vesicular stomatitis virus (VSV)-induced cytopathicity by 50% in HeLa cell lines
Effective concentration required to inhibit vesicular stomatitis virus (VSV)-induced cytopathicity by 50% in HeLa cell lines
|
[PMID: 11495586] |
| HeLa | CC50 |
>50 μg/mL
Compound: Ganciclovir
|
Cytotoxicity against Varicella Zoster Virus infected human HeLa cells assessed as change in cell morphology
Cytotoxicity against Varicella Zoster Virus infected human HeLa cells assessed as change in cell morphology
|
[PMID: 19324473] |
| HeLa | CC50 |
190 μg/mL
Compound: Ganciclovir
|
Cytotoxicity against Varicella Zoster Virus infected human HeLa cells assessed as reduction in cell growth
Cytotoxicity against Varicella Zoster Virus infected human HeLa cells assessed as reduction in cell growth
|
[PMID: 19324473] |
| HeLa | CC50 |
221.8 μM
Compound: Ganciclovir
|
Cytotoxicity against human HeLa cells assessed as cell viability by colorimetric formazan-based MTS assay
Cytotoxicity against human HeLa cells assessed as cell viability by colorimetric formazan-based MTS assay
|
[PMID: 22459876] |
| HeLa | CC50 |
>50 μg/mL
Compound: Ganciclovir
|
Cytotoxic activity was measured in human embryonic lung cells (HeLa)
Cytotoxic activity was measured in human embryonic lung cells (HeLa)
|
10.1016/S0960-894X(97)00149-2 |
| HEp-2 | EC50 |
26.7 μg/mL
Compound: gancyclovir
|
Antiviral activity against VZV 3CV-1 infected in human Hep2 cells after 3 days by plaque neutralization assay
Antiviral activity against VZV 3CV-1 infected in human Hep2 cells after 3 days by plaque neutralization assay
|
[PMID: 9599250] |
| HEp-2 | EC50 |
5 μg/mL
Compound: gancyclovir
|
Antiviral activity against mCMV RM461 infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days
Antiviral activity against mCMV RM461 infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days
|
[PMID: 9599250] |
| HEp-2 | IC50 |
>100 μg/mL
Compound: gancyclovir
|
Cytotoxicity against mCMV RM-461 infected human Hep2 cells after 3 days
Cytotoxicity against mCMV RM-461 infected human Hep2 cells after 3 days
|
[PMID: 9599250] |
| HEp-2 | IC50 |
840 μg/mL
Compound: gancyclovir
|
Cytotoxicity against VZV 3CV-1 infected human Hep2 cells after 3 days
Cytotoxicity against VZV 3CV-1 infected human Hep2 cells after 3 days
|
[PMID: 9599250] |
| Hepatocyte | EC50 |
1.5 μg/mL
Compound: GCV, Ganciclovir
|
Concentration required to reduce the viral DNA in infected cells to 50% of untreated infected controls of Hepatitis B virus in primary duck hepatocyte (DHBV) cultures
Concentration required to reduce the viral DNA in infected cells to 50% of untreated infected controls of Hepatitis B virus in primary duck hepatocyte (DHBV) cultures
|
[PMID: 11985471] |
| HFF | IC50 |
>100 μM
Compound: Ganciclovir
|
Visual cytotoxicity against stationary human foreskin fibroblasts (HFF) cells at the time of HCMV plaque enumeration
Visual cytotoxicity against stationary human foreskin fibroblasts (HFF) cells at the time of HCMV plaque enumeration
|
[PMID: 10882370] |
| HFF | IC50 |
7.4 μM
Compound: Ganciclovir
|
Antiviral activity against towne strain HCMV was determined by plaque reduction assay in duplicate wells using HFF cells
Antiviral activity against towne strain HCMV was determined by plaque reduction assay in duplicate wells using HFF cells
|
[PMID: 10882370] |
| HFF | IC50 |
>100 μM
Compound: Ganciclovir
|
Visual cytotoxicity was scored on HFF cells at time of HCMV plaque enumeration
Visual cytotoxicity was scored on HFF cells at time of HCMV plaque enumeration
|
[PMID: 10882372] |
| HFF | IC50 |
7.4 μM
Compound: Ganciclovir
|
Antiviral activity against HCMV was determined by plaque reduction assay using HFF cells
Antiviral activity against HCMV was determined by plaque reduction assay using HFF cells
|
[PMID: 10882372] |
| HFF | IC50 |
>100 μM
Compound: 1, Gancyclovir
|
Compound was tested for visual cytotoxicity on HFF cells unaffected by HCMV at the time of plaque enumeration
Compound was tested for visual cytotoxicity on HFF cells unaffected by HCMV at the time of plaque enumeration
|
[PMID: 10882374] |
| HFF | IC50 |
4.1 μM
Compound: 1, Gancyclovir
|
Compound was tested for antiviral activity against C-4 Towne strain of HCMV in yield reduction assay using HFF cells
Compound was tested for antiviral activity against C-4 Towne strain of HCMV in yield reduction assay using HFF cells
|
[PMID: 10882374] |
| HFF | IC50 |
4.5 μM
Compound: 1, Gancyclovir
|
Compound was tested for antiviral activity against wild-type Towne strain of HCMV in yield reduction assay using HFF cells
Compound was tested for antiviral activity against wild-type Towne strain of HCMV in yield reduction assay using HFF cells
|
[PMID: 10882374] |
| HFF | IC50 |
7.4 μM
Compound: 1, Gancyclovir
|
Compound was tested for antiviral activity against Towne strain of HCMV in a plaque reduction assay using HFF cells
Compound was tested for antiviral activity against Towne strain of HCMV in a plaque reduction assay using HFF cells
|
[PMID: 10882374] |
| HFF | IC50 |
>100 μM
Compound: Ganciclovir
|
Compound was tested for visual cytotoxicity on human foreskin fibroblasts (HFF) cells
Compound was tested for visual cytotoxicity on human foreskin fibroblasts (HFF) cells
|
[PMID: 10882375] |
| HFF | IC50 |
7.4 μM
Compound: Ganciclovir
|
Compound was tested for antiviral activity against human cytomegalovirus (HCMV) by plaque reduction assay using HFF cells
Compound was tested for antiviral activity against human cytomegalovirus (HCMV) by plaque reduction assay using HFF cells
|
[PMID: 10882375] |
| HFF | IC50 |
0.6 μM
Compound: Ganciclovir
|
Antiviral activity in a cell-based plaque reduction assay, using an HFF cell line and the Davis strain of HCMV
Antiviral activity in a cell-based plaque reduction assay, using an HFF cell line and the Davis strain of HCMV
|
[PMID: 10999475] |
| HFF | CC50 |
>100 μM
Compound: Ganciclovir
|
In vitro cytotoxic concentration required to inhibit towne strain of human cytomegalovirus (HCMV) replication in HFF cell line
In vitro cytotoxic concentration required to inhibit towne strain of human cytomegalovirus (HCMV) replication in HFF cell line
|
[PMID: 14736238] |
| HFF | CC50 |
>392 μM
Compound: Ganciclovir
|
In vitro cytotoxic concentration required to inhibit AD169 strain of human cytomegalovirus (HCMV) replication in HFF cell line
In vitro cytotoxic concentration required to inhibit AD169 strain of human cytomegalovirus (HCMV) replication in HFF cell line
|
[PMID: 14736238] |
| HFF | EC50 |
2.3 μM
Compound: Ganciclovir
|
In vitro effective concentration required to inhibit AD169 strain of human cytomegalovirus (HCMV) replication in HFF cell line
In vitro effective concentration required to inhibit AD169 strain of human cytomegalovirus (HCMV) replication in HFF cell line
|
[PMID: 14736238] |
| HFF | EC50 |
4.1 μM
Compound: Ganciclovir
|
In vitro effective concentration required to inhibit towne strain of human cytomegalovirus (HCMV) replication in HFF cell line
In vitro effective concentration required to inhibit towne strain of human cytomegalovirus (HCMV) replication in HFF cell line
|
[PMID: 14736238] |
| HFF | IC50 |
>100 μM
Compound: GCV
|
Concentration required to inhibit stationary human HFF cell line growth was determined by microscopy examination
Concentration required to inhibit stationary human HFF cell line growth was determined by microscopy examination
|
[PMID: 15509173] |
| HFF | IC50 |
>100 μM
Compound: GCV (ganciclovir) (table-1)
|
Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells
Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells
|
[PMID: 15509174] |
| HFF | IC50 |
7.4 μM
Compound: GCV (ganciclovir) (table-1)
|
Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay
Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay
|
[PMID: 15509174] |
| HFF | IC50 |
>100 μM
Compound: GCV (ganciclovir) (table-1)
|
Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells
Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells
|
[PMID: 15509175] |
| HFF | IC50 |
7.4 μM
Compound: GCV (ganciclovir) (table-1)
|
Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay
Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay
|
[PMID: 15509175] |
| HFF | IC50 |
>100 μM
Compound: GCV (table-1)
|
Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells
Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells
|
[PMID: 15509176] |
| HFF | IC50 |
1.2 μM
Compound: GCV (table-1)
|
Inhibitory concentration required against human cytomegalovirus (HCMV) D10 strain (UL89 mutant gene) expressed in HFF cells was determined by plaque reduction assay
Inhibitory concentration required against human cytomegalovirus (HCMV) D10 strain (UL89 mutant gene) expressed in HFF cells was determined by plaque reduction assay
|
[PMID: 15509176] |
| HFF | IC50 |
1.2 μM
Compound: GCV (table-1)
|
Inhibitory concentration required against human cytomegalovirus (HCMV) r56 strain (UL56 mutant gene) expressed in HFF cells was determined by plaque reduction assay
Inhibitory concentration required against human cytomegalovirus (HCMV) r56 strain (UL56 mutant gene) expressed in HFF cells was determined by plaque reduction assay
|
[PMID: 15509176] |
| HFF | IC50 |
1.2 μM
Compound: GCV (table-1)
|
Inhibitory concentration required against human cytomegalovirus (HCMV) wild type expressed in HFF cells was determined by plaque reduction assay
Inhibitory concentration required against human cytomegalovirus (HCMV) wild type expressed in HFF cells was determined by plaque reduction assay
|
[PMID: 15509176] |
| HFF | IC50 |
2.5 μM
Compound: GCV (table-1)
|
Inhibitory concentration required against human cytomegalovirus (HCMV) C4 strain (UL56 + UL89 mutant gene) expressed in HFF cells was determined by plaque reduction assay
Inhibitory concentration required against human cytomegalovirus (HCMV) C4 strain (UL56 + UL89 mutant gene) expressed in HFF cells was determined by plaque reduction assay
|
[PMID: 15509176] |
| HFF | IC50 |
7.4 μM
Compound: GCV (table-1)
|
Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay
Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay
|
[PMID: 15509176] |
| HFF | CC50 |
>100 μM
Compound: ganciclovir
|
Cytotoxicity against HFF cells by visual cytotoxicity
Cytotoxicity against HFF cells by visual cytotoxicity
|
[PMID: 15615545] |
| HFF | CC50 |
>392 μM
Compound: ganciclovir
|
Cytotoxicity against HFF cells by neutral red uptake assay
Cytotoxicity against HFF cells by neutral red uptake assay
|
[PMID: 15615545] |
| HFF | EC50 |
2.1 μM
Compound: ganciclovir
|
Inhibition of HCMV Towne replication in HFF cells by plaque reduction assay
Inhibition of HCMV Towne replication in HFF cells by plaque reduction assay
|
[PMID: 15615545] |
| HFF | EC50 |
2.2 μM
Compound: ganciclovir
|
Inhibition of HCMV AD169 replication in HFF cells by CPE inhibition assay
Inhibition of HCMV AD169 replication in HFF cells by CPE inhibition assay
|
[PMID: 15615545] |
| HFF | CC50 |
>100 μM
Compound: Ganciclovir
|
Cytotoxic concentration against town strain of human cytomegalovirus infected HFF cells of human (visual cytotoxicity)
Cytotoxic concentration against town strain of human cytomegalovirus infected HFF cells of human (visual cytotoxicity)
|
[PMID: 15634003] |
| HFF | CC50 |
>392 μM
Compound: Ganciclovir
|
Cytotoxic concentration against AD169 strain of human cytomegalovirus infected HFF cells of human (by neutral red uptake)
Cytotoxic concentration against AD169 strain of human cytomegalovirus infected HFF cells of human (by neutral red uptake)
|
[PMID: 15634003] |
| HFF | CC50 |
>100 μM
Compound: ganciclovir
|
Toxicity on uninfected human foreskin fibroblast cells determined in microscopic evaluation and quantitative neutral red dye uptake assay
Toxicity on uninfected human foreskin fibroblast cells determined in microscopic evaluation and quantitative neutral red dye uptake assay
|
[PMID: 16134946] |
| HFF | IC50 |
0.8 μM
Compound: ganciclovir
|
Antiviral activity against human cytomegalovirus Ad169 (V823A) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO
Antiviral activity against human cytomegalovirus Ad169 (V823A) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO
|
[PMID: 16134946] |
| HFF | IC50 |
0.8 μM
Compound: ganciclovir
|
Antiviral activity against human cytomegalovirus Ad169 (WT) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO
Antiviral activity against human cytomegalovirus Ad169 (WT) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO
|
[PMID: 16134946] |
| HFF | IC50 |
1.3 μM
Compound: ganciclovir
|
Antiviral activity against human cytomegalovirus (Davis strain) grown on human foreskin fibroblast cells determined by reduction in plaque formation upon incubation at 37 degrees C with the compound dissolved in DMSO
Antiviral activity against human cytomegalovirus (Davis strain) grown on human foreskin fibroblast cells determined by reduction in plaque formation upon incubation at 37 degrees C with the compound dissolved in DMSO
|
[PMID: 16134946] |
| HFF | IC50 |
>100 μM
Compound: gcv
|
Cytotoxicity against HFF cells
Cytotoxicity against HFF cells
|
[PMID: 16814545] |
| HFF | CC50 |
>100 μM
Compound: ganciclovir
|
Cytotoxicity against HFF cell by neutral red uptake assay
Cytotoxicity against HFF cell by neutral red uptake assay
|
[PMID: 17004726] |
| HFF | EC50 |
0.15 μM
Compound: ganciclovir
|
Inhibition of HCMV AD169 replication in HFF cells by cytopathic effect assay
Inhibition of HCMV AD169 replication in HFF cells by cytopathic effect assay
|
[PMID: 17004726] |
| HFF | EC50 |
1.8 μM
Compound: ganciclovir
|
Inhibition of HCMV towne replication in HFF cells by plaque reduction assay
Inhibition of HCMV towne replication in HFF cells by plaque reduction assay
|
[PMID: 17004726] |
| HFF | IC50 |
1.3 μM
Compound: GCV
|
Antiviral activity against Human CMV T2211 in HFF cells by SEAP assay
Antiviral activity against Human CMV T2211 in HFF cells by SEAP assay
|
[PMID: 17043128] |
| HFF | IC50 |
1.4 μM
Compound: GCV
|
Antiviral activity against Human CMV T2233 in HFF cells by SEAP assay
Antiviral activity against Human CMV T2233 in HFF cells by SEAP assay
|
[PMID: 17043128] |
| HFF | IC50 |
1.4 μM
Compound: GCV
|
Antiviral activity against Human CMV T2241 in HFF cells by SEAP assay
Antiviral activity against Human CMV T2241 in HFF cells by SEAP assay
|
[PMID: 17043128] |
| HFF | IC50 |
1.9 μM
Compound: GCV
|
Antiviral activity against Human CMV AD169 in HFF cells by PRA
Antiviral activity against Human CMV AD169 in HFF cells by PRA
|
[PMID: 17043128] |
| HFF | IC50 |
10 μM
Compound: GCV
|
Antiviral activity against Human CMV T2293 in HFF cells by PRA
Antiviral activity against Human CMV T2293 in HFF cells by PRA
|
[PMID: 17043128] |
| HFF | IC50 |
12.4 μM
Compound: GCV
|
Antiviral activity against Human CMV T2311 in HFF cells by PRA
Antiviral activity against Human CMV T2311 in HFF cells by PRA
|
[PMID: 17043128] |
| HFF | IC50 |
30.2 μM
Compound: GCV
|
Antiviral activity against Human CMV T2311 in HFF cells by SEAP assay
Antiviral activity against Human CMV T2311 in HFF cells by SEAP assay
|
[PMID: 17043128] |
| HFF | IC50 |
4.1 μM
Compound: GCV
|
Antiviral activity against Human CMV T2291 in HFF cells by PRA
Antiviral activity against Human CMV T2291 in HFF cells by PRA
|
[PMID: 17043128] |
| HFF | IC50 |
5.6 μM
Compound: GCV
|
Antiviral activity against Human CMV T2293 in HFF cells by SEAP assay
Antiviral activity against Human CMV T2293 in HFF cells by SEAP assay
|
[PMID: 17043128] |
| HFF | IC50 |
7.1 μM
Compound: GCV
|
Antiviral activity against Human CMV T2291 in HFF cells by SEAP assay
Antiviral activity against Human CMV T2291 in HFF cells by SEAP assay
|
[PMID: 17043128] |
| HFF | IC50 |
3 μM
Compound: ganciclovir
|
Antiviral activity against HCMV Towne in HFF cells by plaque reduction assay
Antiviral activity against HCMV Towne in HFF cells by plaque reduction assay
|
[PMID: 17161946] |
| HFF | CC50 |
>100 μM
Compound: ganciclovir
|
Cytotoxicity against HFF cells by alamar blue assay
Cytotoxicity against HFF cells by alamar blue assay
|
[PMID: 17329103] |
| HFF | IC50 |
1 μM
Compound: ganciclovir
|
Antiviral activity against HCMV infected HFF cells after 5 days by dot blot assay
Antiviral activity against HCMV infected HFF cells after 5 days by dot blot assay
|
[PMID: 17329103] |
| HFF | CC50 |
>100 μM
Compound: ganciclovir
|
Cytotoxicity against HFF cells after 3 days
Cytotoxicity against HFF cells after 3 days
|
[PMID: 17434304] |
| HFF | IC50 |
1300 nM
Compound: ganciclovir
|
Antiviral activity against HCMV Davis in HFF cells by plaque reduction assay
Antiviral activity against HCMV Davis in HFF cells by plaque reduction assay
|
[PMID: 17434304] |
| HFF | EC50 |
1.1 μM
Compound: GCV
|
Antiviral activity against Cytomegalovirus CMV T2211 infected in HFF cells by SEAP reporter gene assay
Antiviral activity against Cytomegalovirus CMV T2211 infected in HFF cells by SEAP reporter gene assay
|
[PMID: 17709468] |
| HFF | EC50 |
2.6 μM
Compound: GCV
|
Antiviral activity against Cytomegalovirus CMV T2417 with pol A809V mutant infected in HFF cells by SEAP reporter gene assay
Antiviral activity against Cytomegalovirus CMV T2417 with pol A809V mutant infected in HFF cells by SEAP reporter gene assay
|
[PMID: 17709468] |
| HFF | EC50 |
2.7 μM
Compound: GCV
|
Antiviral activity against Cytomegalovirus CMV T2542 with pol T813S mutant infected in HFF cells by SEAP reporter gene assay
Antiviral activity against Cytomegalovirus CMV T2542 with pol T813S mutant infected in HFF cells by SEAP reporter gene assay
|
[PMID: 17709468] |
| HFF | EC50 |
3.5 μM
Compound: GCV
|
Antiviral activity against Cytomegalovirus CMV T2420 with pol G841A mutant infected in HFF cells by SEAP reporter gene assay
Antiviral activity against Cytomegalovirus CMV T2420 with pol G841A mutant infected in HFF cells by SEAP reporter gene assay
|
[PMID: 17709468] |
| HFF | EC50 |
3.9 μM
Compound: GCV
|
Antiviral activity against Cytomegalovirus CMV T2258 with UL97 C592G mutant infected in HFF cells by SEAP reporter gene assay
Antiviral activity against Cytomegalovirus CMV T2258 with UL97 C592G mutant infected in HFF cells by SEAP reporter gene assay
|
[PMID: 17709468] |
| HFF | EC50 |
6.1 μM
Compound: GCV
|
Antiviral activity against Cytomegalovirus CMV T2784 with pol A809V UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay
Antiviral activity against Cytomegalovirus CMV T2784 with pol A809V UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay
|
[PMID: 17709468] |
| HFF | EC50 |
6.6 μM
Compound: GCV
|
Antiviral activity against Cytomegalovirus CMV T2798 with pol T813S UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay
Antiviral activity against Cytomegalovirus CMV T2798 with pol T813S UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay
|
[PMID: 17709468] |
| HFF | EC50 |
8.4 μM
Compound: GCV
|
Antiviral activity against Cytomegalovirus CMV 2817 with pol G841A UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay
Antiviral activity against Cytomegalovirus CMV 2817 with pol G841A UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay
|
[PMID: 17709468] |
| HFF | CC50 |
>100 μM
Compound: 14
|
Cytotoxicity against HFF cells
Cytotoxicity against HFF cells
|
[PMID: 18082410] |
| HFF | EC50 |
2.5 μM
Compound: 14
|
Antiviral activity against Human cytomegalovirus Towne infected in HFF cells by plaque reduction assay
Antiviral activity against Human cytomegalovirus Towne infected in HFF cells by plaque reduction assay
|
[PMID: 18082410] |
| HFF | CC50 |
>100 μM
Compound: Ganciclovir
|
Cytotoxicity against HFF cells after 3 days by neutral red dye uptake assay
Cytotoxicity against HFF cells after 3 days by neutral red dye uptake assay
|
[PMID: 18595689] |
| HFF | IC50 |
16.4 μM
Compound: GCV
|
Antiviral activity against ganciclovir-resistant HCMV3 isolate replication in HFF cells by plaque reduction assay
Antiviral activity against ganciclovir-resistant HCMV3 isolate replication in HFF cells by plaque reduction assay
|
[PMID: 19010684] |
| HFF | IC50 |
3.22 μM
Compound: GCV
|
Antiviral activity against ganciclovir-sensitive HCMV1 isolate replication in HFF cells by plaque reduction assay
Antiviral activity against ganciclovir-sensitive HCMV1 isolate replication in HFF cells by plaque reduction assay
|
[PMID: 19010684] |
| HFF | CC50 |
550 μM
Compound: GCV
|
Cytotoxicity against human foreskin fibroblast after 5 days by MTT assay
Cytotoxicity against human foreskin fibroblast after 5 days by MTT assay
|
[PMID: 19015358] |
| HFF | CC50 |
>100 μM
Compound: 10
|
Cytotoxicity against HFF cells by neutral red uptake assay
Cytotoxicity against HFF cells by neutral red uptake assay
|
[PMID: 19397271] |
| HFF | CC50 |
>100 μM
Compound: 10
|
Cytotoxicity against HFF cells by plaque reduction assay
Cytotoxicity against HFF cells by plaque reduction assay
|
[PMID: 19397271] |
| HFF | IC50 |
1300 nM
Compound: Ganciclovir
|
Antiviral activity against Human cytomegalovirus infected in HFF cells by plaque reduction assay
Antiviral activity against Human cytomegalovirus infected in HFF cells by plaque reduction assay
|
[PMID: 20167488] |
| HFF | CC50 |
550 μM
Compound: GCV
|
Cytotoxicity against human HFF by MTT assay
Cytotoxicity against human HFF by MTT assay
|
[PMID: 20194695] |
| HFF | CC50 |
>100 μM
Compound: Ganciclovir
|
Cytotoxicity against HFF cells after 3 days by neutral red dye uptake assay
Cytotoxicity against HFF cells after 3 days by neutral red dye uptake assay
|
[PMID: 20403696] |
| HFF | IC50 |
1.3 μM
Compound: Ganciclovir
|
Inhibition of HCMV DNA polymerase infected in HFF cells
Inhibition of HCMV DNA polymerase infected in HFF cells
|
[PMID: 20403696] |
| HFF | CC50 |
>100 μM
Compound: GCV
|
Cytotoxicity against human HFF cells infected with Human cytomegalovirus AD169 assessed as viable cells by neutral red uptake assay
Cytotoxicity against human HFF cells infected with Human cytomegalovirus AD169 assessed as viable cells by neutral red uptake assay
|
[PMID: 21376429] |
| HFF | EC50 |
0.04 μM
Compound: GCV
|
Antiviral activity against Human cytomegalovirus (strain AD169) infected in 1 hr pretreated human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay
Antiviral activity against Human cytomegalovirus (strain AD169) infected in 1 hr pretreated human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay
|
[PMID: 21376429] |
| HFF | IC50 |
>100 μM
Compound: Ganciclovir
|
Tested for cytotoxic activity against human foreskin fibroblasts (HFF) cells.
Tested for cytotoxic activity against human foreskin fibroblasts (HFF) cells.
|
[PMID: 2163453] |
| HFF | IC50 |
>100 μM
Compound: ganciclovir (DHPG)
|
Compound was evaluated for cytotoxic activity against HFF cells
Compound was evaluated for cytotoxic activity against HFF cells
|
[PMID: 2163454] |
| HFF | IC50 |
3 μM
Compound: Ganciclovir
|
Antiviral activity against Human cytomegalovirus Towne infected in HFF cells assessed as reduction in plaque formation after 10 days
Antiviral activity against Human cytomegalovirus Towne infected in HFF cells assessed as reduction in plaque formation after 10 days
|
[PMID: 21641218] |
| HFF | IC50 |
>100 μM
Compound: Ganciclovir
|
Tested in vitro for cytotoxicity against the normal human diploid cells (HFF cells).
Tested in vitro for cytotoxicity against the normal human diploid cells (HFF cells).
|
[PMID: 2175356] |
| HFF | IC50 |
>100 μM
Compound: GCV
|
Cytotoxicity against HFF cells after 48 hrs by visual cytotoxicity observation assay
Cytotoxicity against HFF cells after 48 hrs by visual cytotoxicity observation assay
|
[PMID: 21812420] |
| HFF | IC50 |
0.14 μM
Compound: GCV
|
Antiviral activity against HCMV Towne infected in HFF cells incubated for 10 days by plaque reduction assay
Antiviral activity against HCMV Towne infected in HFF cells incubated for 10 days by plaque reduction assay
|
[PMID: 21812420] |
| HFF | CC50 |
>300 μM
Compound: GCV
|
Cytotoxicity against human HFF cells after 3 to 8 days by crystal voilet staining
Cytotoxicity against human HFF cells after 3 to 8 days by crystal voilet staining
|
[PMID: 22607883] |
| HFF | IC50 |
2.1 μM
Compound: GCV
|
Antiviral activity against HCMV infected in human HFF cells assessed as reduction in cytopathic effect after 8 days by plaque reduction assay
Antiviral activity against HCMV infected in human HFF cells assessed as reduction in cytopathic effect after 8 days by plaque reduction assay
|
[PMID: 22607883] |
| HFF | CC50 |
>100 μM
Compound: ganciclovir
|
Cytotoxicity against HFF
Cytotoxicity against HFF
|
[PMID: 26260336] |
| HFF | IC50 |
>100 μM
Compound: ganciclovir
|
The compound was tested for cytotoxicity against human foreskin fibroblast cell
The compound was tested for cytotoxicity against human foreskin fibroblast cell
|
[PMID: 2840500] |
| HFF | IC50 |
>100 μM
Compound: Ganciclovir (DHPG)
|
Cytotoxicity against uninfected human foreskin fibroblast(HFF cells)
Cytotoxicity against uninfected human foreskin fibroblast(HFF cells)
|
[PMID: 2846837] |
| HFF | IC50 |
>100 μM
Compound: Ganciclovir
|
Cytotoxicity was evaluated against the Human diploid cells (HFF)
Cytotoxicity was evaluated against the Human diploid cells (HFF)
|
[PMID: 2913300] |
| HFF | CC50 |
>200 μM
Compound: GCV
|
Cytotoxicity against human HFF cells assessed as reduction in cell viability incubated for 72 hrs or 10 days by MTT assay
Cytotoxicity against human HFF cells assessed as reduction in cell viability incubated for 72 hrs or 10 days by MTT assay
|
[PMID: 32191456] |
| HFF | CC50 |
>150 μM
Compound: Ganciclovir
|
Cytotoxicity against human HFF cells assessed as reduction in cell viability incubated for 14 days by cell titer glo assay
Cytotoxicity against human HFF cells assessed as reduction in cell viability incubated for 14 days by cell titer glo assay
|
[PMID: 34124679] |
| HFF | CC50 |
>50 μM
Compound: 1; GCV
|
Cytotoxicity against HFF cells assessed as cell viability incubated for 168 hrs by MTS-based Cell Titer assay
Cytotoxicity against HFF cells assessed as cell viability incubated for 168 hrs by MTS-based Cell Titer assay
|
[PMID: 35377638] |
| HFF | CC50 |
>150 μM
Compound: Ganciclovir
|
Cytotoxicity against human HFF cells infected with HCMV AD-169 virus assessed as reduction in cell viability by cell titer-glo assay
Cytotoxicity against human HFF cells infected with HCMV AD-169 virus assessed as reduction in cell viability by cell titer-glo assay
|
[PMID: 35754374] |
| HFF | IC50 |
4.4 μg/mL
Compound: DHPG
|
Anti HCMV(human cytomegalovirus) activity in HFF cell line Hs 68 infected with AD619 strain of HCMV(plaque reduction assay).
Anti HCMV(human cytomegalovirus) activity in HFF cell line Hs 68 infected with AD619 strain of HCMV(plaque reduction assay).
|
[PMID: 7562929] |
| HFF | IC50 |
52 μg/mL
Compound: DHPG
|
Anti HCMV(human cytomegalovirus) activity in MRC-5 cells infected with DHPG-resistant D16 strain of HCMV(plaque reduction assay).
Anti HCMV(human cytomegalovirus) activity in MRC-5 cells infected with DHPG-resistant D16 strain of HCMV(plaque reduction assay).
|
[PMID: 7562929] |
| HFF | IC50 |
>100 μM
Compound: Ganciclovir
|
Compound was evaluated for the visual cytotoxicity scored on HFF cells at time of HCMV plaque enumeration
Compound was evaluated for the visual cytotoxicity scored on HFF cells at time of HCMV plaque enumeration
|
[PMID: 7562945] |
| HFF | IC50 |
>100 μM
Compound: Ganciclovir
|
Visual cytotoxicity scored on HFF cells at time of HCMV plaque enumeration
Visual cytotoxicity scored on HFF cells at time of HCMV plaque enumeration
|
[PMID: 7562946] |
| HFF | IC50 |
>100 μM
Compound: Ganciclovir
|
Visual cytotoxicity scored on HFF cells at the time of HCMV plaque enumeration.
Visual cytotoxicity scored on HFF cells at the time of HCMV plaque enumeration.
|
[PMID: 7562947] |
| HFF | IC50 |
>100 μM
Compound: ganciclovir
|
Tested for the visual cytotoxicity on HFF cells at the time of human cytomegalovirus (HCMV) plaque enumeration
Tested for the visual cytotoxicity on HFF cells at the time of human cytomegalovirus (HCMV) plaque enumeration
|
[PMID: 8071942] |
| HFF | IC50 |
>100 μM
Compound: ganciclovir
|
Tested for cytotoxicity in human foreskin fibroblasts at time of HCMV plaque enumeration
Tested for cytotoxicity in human foreskin fibroblasts at time of HCMV plaque enumeration
|
[PMID: 8254613] |
| HFF | EC50 |
0.5 μM
Compound: ganciclovir
|
Inhibitory concentration of the drug against the cytopathic effect for AD169 strain of epstein barr virus-2 (HCMV) in human HFF cells
Inhibitory concentration of the drug against the cytopathic effect for AD169 strain of epstein barr virus-2 (HCMV) in human HFF cells
|
[PMID: 8394933] |
| HFF | IC50 |
>100 μM
Compound: Ganciclovir
|
Visual cytotoxicity of compound on HFF cells at time of HCMV plaque enumeration
Visual cytotoxicity of compound on HFF cells at time of HCMV plaque enumeration
|
[PMID: 8632412] |
| HFF | IC50 |
>100 μM
Compound: Ganciclovir (GCV)
|
Cytotoxicity produced in human foreskin fibroblasts (HFF) cells estimated by visual scoring of cells unaffected by virus infection.
Cytotoxicity produced in human foreskin fibroblasts (HFF) cells estimated by visual scoring of cells unaffected by virus infection.
|
[PMID: 8784444] |
| HFF | IC50 |
>100 μM
Compound: ganciclovir
|
Cytotoxicity produced in human foreskin fibroblasts (HFF) cells was estimated by visual scoring of cells unaffected by virus infection in the plaque-reduction assay.
Cytotoxicity produced in human foreskin fibroblasts (HFF) cells was estimated by visual scoring of cells unaffected by virus infection in the plaque-reduction assay.
|
[PMID: 8784445] |
| HFF | IC50 |
>100 μM
Compound: 1
|
Visual cytotoxicity was scored on Human foreskin fibroblasts (HFF cells) at the time of plaque enumeration.
Visual cytotoxicity was scored on Human foreskin fibroblasts (HFF cells) at the time of plaque enumeration.
|
[PMID: 9057865] |
| HFF | IC50 |
7.4 μM
Compound: 1
|
In vitro antiviral activity against HCMV (Towne strain) in HFF (human fibroblast) cells.
In vitro antiviral activity against HCMV (Towne strain) in HFF (human fibroblast) cells.
|
[PMID: 9057865] |
| HFF | IC50 |
>100 μM
Compound: Ganciclovir (DHPG)
|
Cytotoxicity in HFF cells was estimated by the visual scoring of cells affected by virus infection in the plaque reduction assay (data of single experiment)
Cytotoxicity in HFF cells was estimated by the visual scoring of cells affected by virus infection in the plaque reduction assay (data of single experiment)
|
[PMID: 9057866] |
| HFF | IC50 |
7.7 μM
Compound: Ganciclovir (DHPG)
|
Antiviral activity was determined by the HCMV plaque assay using HFF cells
Antiviral activity was determined by the HCMV plaque assay using HFF cells
|
[PMID: 9057866] |
| HFF | IC50 |
>100 μM
Compound: Ganciclovir (DHPG)
|
Visual cytotoxicity was scored on HFF cells at time of HCMV plaque enumeration
Visual cytotoxicity was scored on HFF cells at time of HCMV plaque enumeration
|
[PMID: 9057867] |
| HFF | IC50 |
>100 μM
Compound: Ganciclovir(DHPG)
|
Visual cytotoxicity was scored on HFF cells at time of HCMV plaque enumeration
Visual cytotoxicity was scored on HFF cells at time of HCMV plaque enumeration
|
[PMID: 9057868] |
| HFF | IC50 |
2.6 μM
Compound: Ganciclovir
|
Inhibitory concentration against human cytomegalovirus replication in HFF cells was determined by cytopathic effect inhibition assay
Inhibitory concentration against human cytomegalovirus replication in HFF cells was determined by cytopathic effect inhibition assay
|
[PMID: 9438017] |
| HFF | IC50 |
7.4 μM
Compound: Ganciclovir
|
Inhibitory concentration against human cytomegalovirus replication in HFF cells was determined by plaque reduction assay
Inhibitory concentration against human cytomegalovirus replication in HFF cells was determined by plaque reduction assay
|
[PMID: 9438017] |
| HFF | IC50 |
>100 μM
Compound: Ganciclovir
|
Cytotoxicity for the compound was determined in uninfected stationary human foreskin fibroblasts (HFF) cells.
Cytotoxicity for the compound was determined in uninfected stationary human foreskin fibroblasts (HFF) cells.
|
[PMID: 9548814] |
| HFF | IC50 |
>100 μM
Compound: Ganciclovir
|
Compound was evaluated for the cytotoxicity scored on HFF cells at time of HCMV plaque enumeration.
Compound was evaluated for the cytotoxicity scored on HFF cells at time of HCMV plaque enumeration.
|
[PMID: 9575044] |
| HFF | IC50 |
8.4 μM
Compound: Ganciclovir
|
In vitro inhibition of human cytomegalovirus in HFF cells by plaque reduction assay.
In vitro inhibition of human cytomegalovirus in HFF cells by plaque reduction assay.
|
10.1016/S0960-894X(00)80470-9 |
| HFF | IC50 |
>100 μM
Compound: DHPG
|
Cytotoxicity against human foreskin fibroblasts (HFF) cells
Cytotoxicity against human foreskin fibroblasts (HFF) cells
|
10.1016/S0960-894X(00)80628-9 |
| HS27 | CC50 |
>333 μM
Compound: GCV, Ganciclovir
|
Cytotoxicity against human HS27 cells infected with human cytomegalovirus after 7 days by alamar blue assay
Cytotoxicity against human HS27 cells infected with human cytomegalovirus after 7 days by alamar blue assay
|
[PMID: 20047911] |
| HS27 | EC50 |
0.32 μM
Compound: GCV, Ganciclovir
|
Antiviral activity against human cytomegalovirus infected in human HS27 cells after 7 days by GFP-based fluorescent reduction assay
Antiviral activity against human cytomegalovirus infected in human HS27 cells after 7 days by GFP-based fluorescent reduction assay
|
[PMID: 20047911] |
| Hs68 | CC50 |
12.5 μg/mL
Compound: ganciclovir
|
Cytotoxicity in the Hs 68 cell line
Cytotoxicity in the Hs 68 cell line
|
[PMID: 10447945] |
| Hs68 | CC50 |
12.5 μg/mL
Compound: GCV
|
Cytotoxic activity in Hs 68 cell line by inhibition of cell proliferation
Cytotoxic activity in Hs 68 cell line by inhibition of cell proliferation
|
[PMID: 10888336] |
| HSV-2 | ED50 |
3 μg/mL
Compound: 2a(GCV)
|
Antiviral activity against HSV-2 cell line (concentration required to prevent viral cytopathic effect in half of primary rabbit kidney cell cultures)
Antiviral activity against HSV-2 cell line (concentration required to prevent viral cytopathic effect in half of primary rabbit kidney cell cultures)
|
[PMID: 2848125] |
| Jurkat | IC50 |
>100 μM
Compound: gcv
|
Cytotoxicity against human Jurkat cells
Cytotoxicity against human Jurkat cells
|
[PMID: 16814545] |
| Jurkat | CC50 |
>100 μM
Compound: ganciclovir
|
Cytotoxicity against human Jurkat cells by alamar blue assay
Cytotoxicity against human Jurkat cells by alamar blue assay
|
[PMID: 17329103] |
| KB | IC50 |
>100 μM
Compound: Ganciclovir
|
Compound was tested for the inhibition of KB cell growth in quadruplicate wells
Compound was tested for the inhibition of KB cell growth in quadruplicate wells
|
[PMID: 10882370] |
| KB | IC50 |
>100 μM
Compound: Ganciclovir
|
Inhibition of KB cell growth was determined.
Inhibition of KB cell growth was determined.
|
[PMID: 10882372] |
| KB | IC50 |
>100 μM
Compound: 1, Gancyclovir
|
Compound was tested for inhibition of KB cell growth in quadruplicate assay
Compound was tested for inhibition of KB cell growth in quadruplicate assay
|
[PMID: 10882374] |
| KB | IC50 |
>100 μM
Compound: Ganciclovir
|
Cytotoxicity of compound was determined by assaying cell growth in human neoplastic cell line(KB).
Cytotoxicity of compound was determined by assaying cell growth in human neoplastic cell line(KB).
|
[PMID: 1310744] |
| KB | IC50 |
>100 μM
Compound: GCV
|
Concentration required to inhibit KB cell line growth was determined by crystal violet staining method
Concentration required to inhibit KB cell line growth was determined by crystal violet staining method
|
[PMID: 15509173] |
| KB | IC50 |
>100 μM
Compound: GCV (ganciclovir) (table-1)
|
Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells
Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells
|
[PMID: 15509174] |
| KB | IC50 |
>100 μM
Compound: GCV (ganciclovir) (table-1)
|
Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells
Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells
|
[PMID: 15509175] |
| KB | IC50 |
>100 μM
Compound: GCV (table-1)
|
Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells
Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells
|
[PMID: 15509176] |
| KB | IC50 |
1 mM
Compound: Ganciclovir
|
Tested for cytotoxic activity against human neoplastic cell line(KB cells).
Tested for cytotoxic activity against human neoplastic cell line(KB cells).
|
[PMID: 2163453] |
| KB | IC50 |
>100 μM
Compound: Ganciclovir
|
Tested in vitro for cytotoxicity against the human neoplastic cell line (KB cells).
Tested in vitro for cytotoxicity against the human neoplastic cell line (KB cells).
|
[PMID: 2175356] |
| KB | IC50 |
1 mM
Compound: Ganciclovir (DHPG)
|
Cytotoxicity against human neoplastic cell line (KB)
Cytotoxicity against human neoplastic cell line (KB)
|
[PMID: 2500527] |
| KB | IC50 |
1 mM
Compound: ganciclovir
|
Average percent inhibition of DNA, RNA, and protein synthesis determined in KB cells
Average percent inhibition of DNA, RNA, and protein synthesis determined in KB cells
|
[PMID: 2840500] |
| KB | IC50 |
1 mM
Compound: Ganciclovir
|
Cytotoxicity was evaluated in Human neoplastic cell line (KB)
Cytotoxicity was evaluated in Human neoplastic cell line (KB)
|
[PMID: 2913300] |
| KB | IC50 |
>100 μM
Compound: Ganciclovir
|
Compound was evaluated for the inhibition of KB cell growth determined in quadruplicate assay
Compound was evaluated for the inhibition of KB cell growth determined in quadruplicate assay
|
[PMID: 7562945] |
| KB | IC50 |
>100 μM
Compound: Ganciclovir
|
cell growth inhibition was determined in KB cells in quadruplicate assays
cell growth inhibition was determined in KB cells in quadruplicate assays
|
[PMID: 7562946] |
| KB | IC50 |
>100 μM
Compound: Ganciclovir
|
In vitro inhibition of KB cell proliferation.
In vitro inhibition of KB cell proliferation.
|
[PMID: 7562947] |
| KB | IC50 |
>100 μM
Compound: ganciclovir
|
Tested for the inhibition of KB cell growth
Tested for the inhibition of KB cell growth
|
[PMID: 8254613] |
| KB | IC50 |
>100 μM
Compound: Ganciclovir
|
Inhibitory activity of compound against KB cell growth [>-indicates IC50/IC90 was not reached at the noted (highest) concentration tested]
Inhibitory activity of compound against KB cell growth [>-indicates IC50/IC90 was not reached at the noted (highest) concentration tested]
|
[PMID: 8632412] |
| KB | IC50 |
>320 μM
Compound: Ganciclovir (GCV)
|
Cytotoxicity (growth inhibition) against human epidermoid oral carcinoma KB cell line.
Cytotoxicity (growth inhibition) against human epidermoid oral carcinoma KB cell line.
|
[PMID: 8784444] |
| KB | IC50 |
>100 μM
Compound: ganciclovir
|
Inhibitory activity against growth of KB cell.
Inhibitory activity against growth of KB cell.
|
[PMID: 8784445] |
| KB | IC50 |
>100 μM
Compound: 1
|
In vitro inhibition of KB (human carcinoma) cell growth.
In vitro inhibition of KB (human carcinoma) cell growth.
|
[PMID: 9057865] |
| KB | IC50 |
>100 μM
Compound: Ganciclovir (DHPG)
|
Cytotoxicity in KB cells.
Cytotoxicity in KB cells.
|
[PMID: 9057866] |
| KB | IC50 |
3.5 μM
Compound: Ganciclovir (DHPG)
|
Antiviral activity was estimated by HSV-1 ELISA method (data of single experiment)
Antiviral activity was estimated by HSV-1 ELISA method (data of single experiment)
|
[PMID: 9057866] |
| KB | IC50 |
>100 μM
Compound: Ganciclovir (DHPG)
|
Inhibition of KB cell growth was determined
Inhibition of KB cell growth was determined
|
[PMID: 9057867] |
| KB | IC50 |
>100 μM
Compound: Ganciclovir(DHPG)
|
Inhibition of KB cell growth was determined
Inhibition of KB cell growth was determined
|
[PMID: 9057868] |
| KB | IC50 |
>100 μM
Compound: Ganciclovir
|
Cytotoxicity for the compound was determined by the inhibition of the growing KB cells.
Cytotoxicity for the compound was determined by the inhibition of the growing KB cells.
|
[PMID: 9548814] |
| KB | IC50 |
>100 μM
Compound: Ganciclovir
|
Compound was evaluated for the cytotoxicity by the inhibition of KB cell growth.
Compound was evaluated for the cytotoxicity by the inhibition of KB cell growth.
|
[PMID: 9575044] |
| MEF | CC50 |
>35 μM
Compound: Ganciclovir
|
In vitro cytotoxic concentration required to inhibit murine cytomegalovirus (MCMV) replication in MEF cell line
In vitro cytotoxic concentration required to inhibit murine cytomegalovirus (MCMV) replication in MEF cell line
|
[PMID: 14736238] |
| MEF | EC50 |
5 μM
Compound: Ganciclovir
|
In vitro effective concentration required to inhibit murine cytomegalovirus (MCMV) replication in MEF cell line
In vitro effective concentration required to inhibit murine cytomegalovirus (MCMV) replication in MEF cell line
|
[PMID: 14736238] |
| MEF | CC50 |
>392 μM
Compound: Ganciclovir
|
Cytotoxic concentration against murine cytomegalovirus infected MEF cells
Cytotoxic concentration against murine cytomegalovirus infected MEF cells
|
[PMID: 15634003] |
| MEF | EC50 |
0.96 μM
Compound: GCV
|
Antiviral activity against Mouse Cytomegalovirus Smith (ATCC VR-1399) infected in mouse MEF cells assessed as reduction in plaque formation measured after 3 days by crystal violet staining based assay
Antiviral activity against Mouse Cytomegalovirus Smith (ATCC VR-1399) infected in mouse MEF cells assessed as reduction in plaque formation measured after 3 days by crystal violet staining based assay
|
[PMID: 32191456] |
| MEF | IC50 |
3.4 μM
Compound: Ganciclovir
|
Inhibitory concentration against murine cytomegalovirus replication in MEF cells was determined by plaque reduction assay
Inhibitory concentration against murine cytomegalovirus replication in MEF cells was determined by plaque reduction assay
|
[PMID: 9438017] |
| MRC5 | CC50 |
98 μM
Compound: ganciclovir
|
Concentration required to reduce MRC-5 cell growth by 50%
Concentration required to reduce MRC-5 cell growth by 50%
|
[PMID: 10966740] |
| MRC5 | IC50 |
5.9 μM
Compound: ganciclovir
|
Concentration required to reduce viral plaque formation by Human Cytomegalovirus (HCMV) (strain AD-169) in MRC-5 cells
Concentration required to reduce viral plaque formation by Human Cytomegalovirus (HCMV) (strain AD-169) in MRC-5 cells
|
[PMID: 10966740] |
| MRC5 | IC50 |
>10 μM
Compound: GCV
|
Inhibitory concentration against Xba F strain of HCMV in MRC5 cells
Inhibitory concentration against Xba F strain of HCMV in MRC5 cells
|
[PMID: 11454465] |
| MRC5 | IC50 |
1.4 μM
Compound: GCV
|
Inhibitory concentration against Davis strain of HCMV in MRC5 cells
Inhibitory concentration against Davis strain of HCMV in MRC5 cells
|
[PMID: 11454465] |
| MRC5 | IC50 |
1.5 μM
Compound: GCV
|
Inhibitory concentration against Towne strain of HCMV in MRC5 cells
Inhibitory concentration against Towne strain of HCMV in MRC5 cells
|
[PMID: 11454465] |
| MRC5 | IC50 |
1.6 μM
Compound: GCV
|
Inhibitory concentration against 2599R strain of HCMV in MRC5 cells
Inhibitory concentration against 2599R strain of HCMV in MRC5 cells
|
[PMID: 11454465] |
| MRC5 | IC50 |
3 μM
Compound: GCV
|
Inhibitory concentration against AD169 strain of HCMV in MRC5 cells
Inhibitory concentration against AD169 strain of HCMV in MRC5 cells
|
[PMID: 11454465] |
| MRC5 | EC50 |
9.4 μM
Compound: ganciclovir
|
Inhibitory activity of compound against human cytomegalovirus (HCMV) in MRC-5 cells.
Inhibitory activity of compound against human cytomegalovirus (HCMV) in MRC-5 cells.
|
[PMID: 12723951] |
| MRC5 | IC50 |
4 μM
Compound: ganciclovir
|
In vitro antiherpesvirus activity against MRC-5 cells infected with HCMV (AD-169 strain)
In vitro antiherpesvirus activity against MRC-5 cells infected with HCMV (AD-169 strain)
|
[PMID: 1323678] |
| MRC5 | IC50 |
1.2 μg/mL
Compound: Ganciclovir
|
Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory strains P8 using MRC-5 cell line
Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory strains P8 using MRC-5 cell line
|
[PMID: 15745823] |
| MRC5 | IC50 |
2.2 μg/mL
Compound: Ganciclovir
|
Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory strains Ad169 using MRC-5 cell line
Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory strains Ad169 using MRC-5 cell line
|
[PMID: 15745823] |
| MRC5 | IC50 |
7.8 μg/mL
Compound: Ganciclovir
|
Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory mutant strains D16(UL54 mutation) using MRC-5 cell line
Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory mutant strains D16(UL54 mutation) using MRC-5 cell line
|
[PMID: 15745823] |
| MRC5 | IC50 |
8.7 μg/mL
Compound: Ganciclovir
|
Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory mutant strains C8704(UL97 mutation) using MRC-5 cell line
Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory mutant strains C8704(UL97 mutation) using MRC-5 cell line
|
[PMID: 15745823] |
| MRC5 | IC50 |
30.1 μM
Compound: GCV
|
Antiviral activity against Human CMV T2287 in MRC5 cells by PRA
Antiviral activity against Human CMV T2287 in MRC5 cells by PRA
|
[PMID: 17043128] |
| MRC5 | IC50 |
4.9 μM
Compound: GCV
|
Antiviral activity against Human CMV Towne in MRC5 cells by PRA
Antiviral activity against Human CMV Towne in MRC5 cells by PRA
|
[PMID: 17043128] |
| MRC5 | IC50 |
5.4 μM
Compound: GCV
|
Antiviral activity against Human CMV T2296 in MRC5 cells by PRA
Antiviral activity against Human CMV T2296 in MRC5 cells by PRA
|
[PMID: 17043128] |
| MRC5 | IC50 |
0.91 μM
Compound: GCV
|
Antiviral activity against HCMV in MRC5 cells by plaque reduction assay
Antiviral activity against HCMV in MRC5 cells by plaque reduction assay
|
[PMID: 17239594] |
| MRC5 | IC50 |
970 μM
Compound: GCV
|
Cytotoxicity against MRC5 cells
Cytotoxicity against MRC5 cells
|
[PMID: 17239594] |
| MRC5 | CC50 |
>333 μM
Compound: GCV, Ganciclovir
|
Cytotoxicity against human MRC5 cells infected with human cytomegalovirus after 7 days by alamar blue assay
Cytotoxicity against human MRC5 cells infected with human cytomegalovirus after 7 days by alamar blue assay
|
[PMID: 20047911] |
| MRC5 | EC50 |
1.65 μM
Compound: GCV, Ganciclovir
|
Antiviral activity against human cytomegalovirus infected in human MRC5 cells after 7 days by GFP-based fluorescent reduction assay
Antiviral activity against human cytomegalovirus infected in human MRC5 cells after 7 days by GFP-based fluorescent reduction assay
|
[PMID: 20047911] |
| MRC5 | ED50 |
0.4 μg/mL
Compound: 2' NDG
|
In vitro anti viral activity tested against HCMV(AD169) virus on MRC-5 cell monolayers; 0.4-1.6
In vitro anti viral activity tested against HCMV(AD169) virus on MRC-5 cell monolayers; 0.4-1.6
|
[PMID: 2989523] |
| MRC5 | ED50 |
1 μg/mL
Compound: 2' NDG
|
In vitro anti viral activity tested against VZV(KMcC) virus on MRC-5 cell monolayers; 1-2
In vitro anti viral activity tested against VZV(KMcC) virus on MRC-5 cell monolayers; 1-2
|
[PMID: 2989523] |
| MRC5 | CC50 |
>100 μM
Compound: 1
|
Cytotoxicity against human MRC5 cells by CCK-8 assay
Cytotoxicity against human MRC5 cells by CCK-8 assay
|
[PMID: 37037115] |
| MRC5 | IC50 |
3.2 μg/mL
Compound: DHPG
|
Anti HCMV (human cytomegalovirus) activity in MRC-5 cells infected with AD619 strain of HCMV (plaque reduction assay).
Anti HCMV (human cytomegalovirus) activity in MRC-5 cells infected with AD619 strain of HCMV (plaque reduction assay).
|
[PMID: 7562929] |
| MRC5 | IC50 |
1.7 μM
Compound: Ganciclovir
|
In vitro antiviral activity against Human cytomegalovirus (HCMV)strain AD169 in MRC-5 lung fibroblasts using a DNA-hybridization assay
In vitro antiviral activity against Human cytomegalovirus (HCMV)strain AD169 in MRC-5 lung fibroblasts using a DNA-hybridization assay
|
[PMID: 8176714] |
| MRC5 | IC50 |
6.3 μM
Compound: GCV
|
Inhibitory concentration for anti-HCMV activity against AD-169 strain in MRC-5 cells
Inhibitory concentration for anti-HCMV activity against AD-169 strain in MRC-5 cells
|
[PMID: 9836613] |
| MRC5 | CC50 |
>100 μg/mL
Compound: Ganciclovir
|
Compound was tested for cytotoxicity by measuring inhibition of MRC-5 cell proliferation.
Compound was tested for cytotoxicity by measuring inhibition of MRC-5 cell proliferation.
|
[PMID: 9934471] |
| MRC5 | IC50 |
2.1 μg/mL
Compound: Ganciclovir
|
Compound was tested for cytotoxicity by measuring inhibition of MRC-5 cell proliferation.
Compound was tested for cytotoxicity by measuring inhibition of MRC-5 cell proliferation.
|
[PMID: 9934471] |
| MT4 | IC50 |
>50 μM
Compound: 1
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability by cell counting method
Cytotoxicity against human MT4 cells assessed as reduction in cell viability by cell counting method
|
[PMID: 28829913] |
| Neoplastic cell line | IC50 |
>100 μM
Compound: ganciclovir (DHPG)
|
Compound was evaluated for cytotoxic activity against KB cells
Compound was evaluated for cytotoxic activity against KB cells
|
[PMID: 2163454] |
| NHDF | CC50 |
>333 μM
Compound: GCV, Ganciclovir
|
Cytotoxicity against NHDF infected with human cytomegalovirus after 7 days by alamar blue assay
Cytotoxicity against NHDF infected with human cytomegalovirus after 7 days by alamar blue assay
|
[PMID: 20047911] |
| NIH3T3 | EC50 |
5.7 μM
Compound: GCV
|
Antiviral activity against Murine cytomegalovirus strain Smith infected in mouse NIH 3T3 cells after 4 to 5 days by plaque reduction assay
Antiviral activity against Murine cytomegalovirus strain Smith infected in mouse NIH 3T3 cells after 4 to 5 days by plaque reduction assay
|
[PMID: 18458124] |
| OST | IC50 |
0.0019 μM
Compound: GCV
|
Cytotoxicity against human OST TK- cells expressing HSV1 TK
Cytotoxicity against human OST TK- cells expressing HSV1 TK
|
[PMID: 17181158] |
| OST | IC50 |
0.018 μM
Compound: GCV
|
Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 2.5 uM 1-[6-(triphenylmethoxy)hexyl]thymine
Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 2.5 uM 1-[6-(triphenylmethoxy)hexyl]thymine
|
[PMID: 17181158] |
| OST | IC50 |
0.033 μM
Compound: GCV
|
Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 5 uM 1-[6-(triphenylmethoxy)hexyl]thymine
Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 5 uM 1-[6-(triphenylmethoxy)hexyl]thymine
|
[PMID: 17181158] |
| OST | IC50 |
0.041 μM
Compound: GCV
|
Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 10 uM 1-[6-(triphenylmethoxy)hexyl]thymine
Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 10 uM 1-[6-(triphenylmethoxy)hexyl]thymine
|
[PMID: 17181158] |
| OST | IC50 |
0.05 μM
Compound: GCV
|
Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 2.5 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine
Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 2.5 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine
|
[PMID: 17181158] |
| OST | IC50 |
0.081 μM
Compound: GCV
|
Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 5 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine
Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 5 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine
|
[PMID: 17181158] |
| OST | IC50 |
0.11 μM
Compound: GCV
|
Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 10 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine
Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 10 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine
|
[PMID: 17181158] |
| Osteoclast-like | IC50 |
30 μM
Compound: gcv
|
Cytotoxicity against human bone marrow cells assessed as inhibition of colony forming unit of granulocyte/macrophage
Cytotoxicity against human bone marrow cells assessed as inhibition of colony forming unit of granulocyte/macrophage
|
[PMID: 16814545] |
| RG2 | CC50 |
377 μM
Compound: GCV
|
Cytotoxicity against RG2 cells after 72 hrs by MTT assay
Cytotoxicity against RG2 cells after 72 hrs by MTT assay
|
[PMID: 18800764] |
| Vero | EC50 |
0.23 μM
Compound: Ganciclovir
|
Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell in monolayers of HSV-2 AD Vero cells by 50%
Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell in monolayers of HSV-2 AD Vero cells by 50%
|
[PMID: 11585457] |
| Vero | EC50 |
>50 μM
Compound: ganciclovir
|
Inhibition of HSV1 in Vero cells by plaque reduction assay
Inhibition of HSV1 in Vero cells by plaque reduction assay
|
[PMID: 15615545] |
| Vero | EC50 |
>50 μM
Compound: ganciclovir
|
Inhibition of HSV2 in Vero cells by plaque reduction assay
Inhibition of HSV2 in Vero cells by plaque reduction assay
|
[PMID: 15615545] |
| Vero | IC50 |
1.22 μg/mL
Compound: Ganciclovir
|
Compound concentration to reduce virus cytopathic effect by 50% tested against herpes simplex virus-1(G) using Vero cell line
Compound concentration to reduce virus cytopathic effect by 50% tested against herpes simplex virus-1(G) using Vero cell line
|
[PMID: 15745823] |
| Vero | IC50 |
1.274 μg/mL
Compound: Ganciclovir
|
Compound concentration to reduce virus cytopathic effect by 50% tested against herpes simplex virus-1(KOS) using Vero cell line
Compound concentration to reduce virus cytopathic effect by 50% tested against herpes simplex virus-1(KOS) using Vero cell line
|
[PMID: 15745823] |
| Vero | CC50 |
>100 μM
Compound: ganciclovir
|
Toxicity on uninfected African green monkey kidney cells determined in microscopic evaluation and quantitative neutral red dye uptake assay
Toxicity on uninfected African green monkey kidney cells determined in microscopic evaluation and quantitative neutral red dye uptake assay
|
[PMID: 16134946] |
| Vero | CC50 |
666 μM
Compound: GCV
|
Cytotoxicity against african green monkey Vero cells after 2 days
Cytotoxicity against african green monkey Vero cells after 2 days
|
[PMID: 17438061] |
| Vero | EC50 |
0.7 μM
Compound: GCV
|
Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs
Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs
|
[PMID: 17438061] |
| Vero | EC50 |
14.5 μM
Compound: GCV
|
Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs
Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs
|
[PMID: 17438061] |
| Vero | EC50 |
19.2 μM
Compound: GCV
|
Antiviral activity against Herpes B virus E90-136 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs
Antiviral activity against Herpes B virus E90-136 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs
|
[PMID: 17438061] |
| Vero | EC50 |
23.5 μM
Compound: GCV
|
Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs
Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs
|
[PMID: 17438061] |
| Vero | EC50 |
19.3 μM
Compound: GCV
|
Antiviral activity against HSV1 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against HSV1 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259] |
| Vero | EC50 |
19.3 μM
Compound: GCV
|
Antiviral activity against HSV2 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against HSV2 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259] |
| Vero | EC50 |
19.3 μM
Compound: GCV
|
Antiviral activity against Macacine herpesvirus 1 isolate A1 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate A1 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259] |
| Vero | EC50 |
19.3 μM
Compound: GCV
|
Antiviral activity against Macacine herpesvirus 1 isolate A2 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate A2 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259] |
| Vero | EC50 |
19.3 μM
Compound: GCV
|
Antiviral activity against Macacine herpesvirus 1 isolate A3 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate A3 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259] |
| Vero | EC50 |
19.3 μM
Compound: GCV
|
Antiviral activity against Macacine herpesvirus 1 isolate A4 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate A4 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259] |
| Vero | EC50 |
19.3 μM
Compound: GCV
|
Antiviral activity against Macacine herpesvirus 1 isolate A5 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate A5 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259] |
| Vero | EC50 |
19.3 μM
Compound: GCV
|
Antiviral activity against Macacine herpesvirus 1 isolate A6 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate A6 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259] |
| Vero | EC50 |
19.3 μM
Compound: GCV
|
Antiviral activity against Macacine herpesvirus 1 isolate E2490 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate E2490 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259] |
| Vero | EC50 |
19.3 μM
Compound: GCV
|
Antiviral activity against Macacine herpesvirus 1 isolate MC1 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate MC1 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259] |
| Vero | EC50 |
19.3 μM
Compound: GCV
|
Antiviral activity against Macacine herpesvirus 1 isolate MC2 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate MC2 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259] |
| Vero | EC50 |
19.3 μM
Compound: GCV
|
Antiviral activity against Macacine herpesvirus 1 isolate MJ1 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate MJ1 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259] |
| Vero | EC50 |
19.3 μM
Compound: GCV
|
Antiviral activity against Macacine herpesvirus 1 isolate MJ2 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate MJ2 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259] |
| Vero | EC50 |
19.3 μM
Compound: GCV
|
Antiviral activity against Macacine herpesvirus 1 isolate MJ3 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate MJ3 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259] |
| Vero | EC50 |
19.3 μM
Compound: GCV
|
Antiviral activity against Macacine herpesvirus 1 isolate MP1 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate MP1 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259] |
| Vero | EC50 |
19.3 μM
Compound: GCV
|
Antiviral activity against Macacine herpesvirus 1 isolate MR1 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate MR1 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259] |
| Vero | EC50 |
19.3 μM
Compound: GCV
|
Antiviral activity against Macacine herpesvirus 1 isolate MR10 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate MR10 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259] |
| Vero | EC50 |
19.3 μM
Compound: GCV
|
Antiviral activity against Macacine herpesvirus 1 isolate MR11 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate MR11 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259] |
| Vero | EC50 |
19.3 μM
Compound: GCV
|
Antiviral activity against Macacine herpesvirus 1 isolate MR2 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate MR2 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259] |
| Vero | EC50 |
19.3 μM
Compound: GCV
|
Antiviral activity against Macacine herpesvirus 1 isolate MR3 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate MR3 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259] |
| Vero | EC50 |
19.3 μM
Compound: GCV
|
Antiviral activity against Macacine herpesvirus 1 isolate MR4 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate MR4 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259] |
| Vero | EC50 |
19.3 μM
Compound: GCV
|
Antiviral activity against Macacine herpesvirus 1 isolate MR5 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate MR5 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259] |
| Vero | EC50 |
19.3 μM
Compound: GCV
|
Antiviral activity against Macacine herpesvirus 1 isolate MR6 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate MR6 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259] |
| Vero | EC50 |
19.3 μM
Compound: GCV
|
Antiviral activity against Macacine herpesvirus 1 isolate MR7 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate MR7 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259] |
| Vero | EC50 |
19.3 μM
Compound: GCV
|
Antiviral activity against Macacine herpesvirus 1 isolate MR8 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate MR8 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259] |
| Vero | EC50 |
19.3 μM
Compound: GCV
|
Antiviral activity against Macacine herpesvirus 1 isolate MR9 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate MR9 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259] |
| Vero | EC50 |
0.9 μM
Compound: 1b
|
Antiviral activity against Herpes simplex virus 1 strain F VR-733 infected in African green monkey Vero cells after 3 days by MTT assay
Antiviral activity against Herpes simplex virus 1 strain F VR-733 infected in African green monkey Vero cells after 3 days by MTT assay
|
[PMID: 26460883] |
| Vero | EC50 |
1.4 μM
Compound: 1b
|
Antiviral activity against Herpes simplex virus 2 strain MS VR-540 infected in African green monkey Vero cells after 3 days by MTT assay
Antiviral activity against Herpes simplex virus 2 strain MS VR-540 infected in African green monkey Vero cells after 3 days by MTT assay
|
[PMID: 26460883] |
| Vero | EC50 |
11.1 μM
Compound: 1b
|
Antiviral activity against Varicella-zoster virus Ellen VR-1367 infected in African green monkey Vero cells after 3 days by MTT assay
Antiviral activity against Varicella-zoster virus Ellen VR-1367 infected in African green monkey Vero cells after 3 days by MTT assay
|
[PMID: 26460883] |
| Vero | EC50 |
2.14 μM
Compound: 1b
|
Antiviral activity against Human cytomegalovirus Davis VR-807 infected in African green monkey Vero cells after 3 days by MTT assay
Antiviral activity against Human cytomegalovirus Davis VR-807 infected in African green monkey Vero cells after 3 days by MTT assay
|
[PMID: 26460883] |
| Vero | IC50 |
0.1 μM
Compound: 1 (BW-B759U, ganciclovir)
|
Inhibition of growth of herpes simplex virus (HSV-1) by plaque reduction assay in vero cell line
Inhibition of growth of herpes simplex virus (HSV-1) by plaque reduction assay in vero cell line
|
[PMID: 2826784] |
| Vero | IC50 |
0.1 μM
Compound: 1 (BW-B759U, ganciclovir)
|
Inhibition of growth of herpes simplex virus (HSV-2) by plaque reduction assay in vero cell line
Inhibition of growth of herpes simplex virus (HSV-2) by plaque reduction assay in vero cell line
|
[PMID: 2826784] |
| Vero | IC50 |
2.8 μM
Compound: 1 (BW-B759U, ganciclovir)
|
Inhibition of growth of varicella zoster virus(VZV) by plaque reduction assay in vero cell line
Inhibition of growth of varicella zoster virus(VZV) by plaque reduction assay in vero cell line
|
[PMID: 2826784] |
| Vero | EC50 |
0.025 μM
Compound: GCV
|
Antiviral activity against HSV-1 infected in African green monkey Vero cells assessed as inhibition of GFP expression after 72 hrs by GFP-based fluorescence microscopic analysis
Antiviral activity against HSV-1 infected in African green monkey Vero cells assessed as inhibition of GFP expression after 72 hrs by GFP-based fluorescence microscopic analysis
|
[PMID: 31503476] |
| Vero | EC50 |
0.04 μM
Compound: GCV
|
Antiviral activity against HSV 1 infected in African green monkey Vero cells assessed as reduction in plaque formation incubated for 36 hrs by crystal violet staining based assay
Antiviral activity against HSV 1 infected in African green monkey Vero cells assessed as reduction in plaque formation incubated for 36 hrs by crystal violet staining based assay
|
[PMID: 32191456] |
| Vero | EC50 |
0.58 μM
Compound: GCV
|
Antiviral activity against HSV 2 infected in African green monkey Vero cells assessed as reduction in plaque formation incubated for 36 hrs by crystal violet staining based assay
Antiviral activity against HSV 2 infected in African green monkey Vero cells assessed as reduction in plaque formation incubated for 36 hrs by crystal violet staining based assay
|
[PMID: 32191456] |
Ganciclovir (BW 759) is an acyclic deoxyguanosine analog structurally similar to acyclovir but with superior activity against CMV. The median Ganciclovir concentration required to inhibit viral replication by 50 percent is 2.15 μM versus 72 μM for acyclovir[4].
The primary mechanism of Ganciclovir action against CMV is inhibition of the replication of viral DNA by ganciclovir-5'-triphosphate (ganciclovir-TP). This inhibition includes a selective and potent inhibition of the viral DNA polymerase. Ganciclovir is metabolized to the triphosphate form by primarily three cellular enzymes: a deoxyguanosine kinase induced by CMV-infected cells; guanylate kinase; and phosphoglycerate kinase[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Ganciclovir (1-80 mg/kg; i.h.; daily for 5 days) delays murine cytomegalovirus (MCMV)-induced wasting syndrome and mortality[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Non-inbred Oncins France 1 (OF1) mice and albino rats non-immunized for MCMV[3]
-
Dosage:50 mg/kg
-
Administration:Intraperitoneal injection, twice a day for five injections (mice) or 3 days (adult rats) (Pharmacokinetic Study)
-
Result:In adult rats, the intracochlear diffusion of Ganciclovir was shown to achieve the same concentration as in blood. In gestating mice, transplacental diffusion was observed, with a fetal-to-maternal blood ratio of 0.5. In newborn mice, the plasma concentration profile of Ganciclovir showed a peak at 2 h followed by a gradual decrease. In adult mice, the concentration peaked at 1 h, but became undetectable by 2 h after injection.
Significantly decreased white blood cells, red blood cells and platelets in newborn mice.
-
Animal Model:Female SCID mice inoculated with MCMV[6]
-
Dosage:0, 1, 10, 80 and 160 mg/kg
-
Administration:Subcutaneous injection, once daily for 5 days
-
Result:Dose dependently delayed the wasting syndrome and mortality in a dose range up to 80 mg/kg per day, whereas a dose of 160 mg/kg per day induced reversible side-effects.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 82410-32-0
-
性状 Solid
-
分子量 255.23
-
分子式 C9H13N5O4
-
Color White to off-white
-
SMILES
O=C1NC(N)=NC2=C1N=CN2COC(CO)CO
-
別名
Ganciclovir; BW 759; 2'-Nor-2'-deoxyguanosine
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (28)
-
Journal Impact Factor
-
Most Recent
-
Cell
2025 Apr 3;188(7):1828-1841.e15. PMID: 39952247 -
Cell
2020 Nov 25;183(5):1402-1419.e18. PMID: 33152263
Ganciclovir purchased from MedChemExpress. Usage Cited in: Cell. 2020 Nov 25;183(5):1402-1419.e18. [Abstract]
In vivo studies of miR-124-HSV-tk-GFP teratomas in the presence of GCV administration (80mg/kg/d, 10 weeks) using both intratumoral (IT) and intratumoral and intraperitoneal injection methods. A heatmap showing cell type fraction log fold-change for each teratoma replicate compared to a control miR-124-HSV-tk-GFP teratoma in the absence of GCV. Z-scores for each cell type fraction change are plotted as well, with standard deviations calculated using a pooled variance.
-
Nat Neurosci
Spatiotemporally selective astrocytic ATP dynamics encode injury information sensed by microglia following brain injury in mice. [Abstract]2024 Aug;27(8):1522-1533. PMID: 38862791 -
Nat Commun
Engineering a synthetic gene circuit for high-performance inducible expression in mammalian systems. [Abstract]2024 Apr 17;15(1):3311. PMID: 38632224 -
Trends Biotechnol
2025 Aug 29:S0167-7799(25)00316-6. PMID: 40885669 -
J Nanobiotechnology
GRP75-driven, cell-cycle-dependent macropinocytosis of Tat/pDNA-Ca2+ nanoparticles underlies distinct gene therapy effect in ovarian cancer. [Abstract]2022 Jul 20;20(1):340. PMID: 35858873
Ganciclovir purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2022 Jul 20;20(1):340. [Abstract]
Long-term GCV (50 mg/kg, ip)-trigged nanoparticle-based therapy in ovarian cancer model.
-
Brain Behav Immun
Conditional ablation of reactive astrocytes to dissect their roles in spinal cord injury and repair. [Abstract]2019 Aug:80:394-405. PMID: 30959174 -
Sci Data
High-content, arrayed compound screens with rhinovirus, influenza A virus and herpes simplex virus infections. [Abstract]2022 Oct 8;9(1):610. PMID: 36209289
Ganciclovir purchased from MedChemExpress. Usage Cited in: Sci Data. 2022 Oct 8;9(1):610. [Abstract]
Exemplary overviews of one screening plate for each virus screen. Individual images of each well were stitched yielding the overviews. First two columns of each plate contained DMSO control solvent, the following 20 columns PCL compounds, and the last two columns the positive controls (BafA1 for RV and IAV, and GCV (25 μM) for HSV-1). Scale bar represents 10 mm.
-
Biochem Pharmacol
Ganciclovir attenuates the onset and progression of experimental autoimmune uveitis by inhibiting infiltration of Th17 and inflammatory cells into the retina. [Abstract]2022 Mar:197:114917. PMID: 35041813 -
Pharmaceutics
Combined Treatment with Host-Directed and Anticytomegaloviral Kinase Inhibitors: Mechanisms, Synergisms and Drug Resistance Barriers. [Abstract]2023 Nov 27;15(12):2680. PMID: 38140021
Ganciclovir purchased from MedChemExpress. Usage Cited in: Pharmaceutics. 2023 Nov 27;15(12):2680. [Abstract]
GCV (1-30 μM) exhibited a dose-dependent decrease in newly synthesized DNA due to its inhibitory impact on the viral polymerase processing activity.
-
Cells
The Thrombopoietin Receptor Agonist Eltrombopag Inhibits Human Cytomegalovirus Replication Via Iron Chelation. [Abstract]2019 Dec 20;9(1):31. PMID: 31861948
Ganciclovir purchased from MedChemExpress. Usage Cited in: Cells. 2019 Dec 20;9(1):31. [Abstract]
Antiviral effects of eltrombopag in combination with Ganciclovir (0.61-10000 nM). Effects of equimolar drug concentrations on HCMV LA expression in HCMV Hi91 (MOI 0.02) HFFs 120 h post infection. * p < 0.05 compared to either single treatment.
-
-
PLoS Pathog
Palmitoylation of KSHV pORF55 is required for Golgi localization and efficient progeny virion production. [Abstract]2024 Apr 16;20(4):e1012141. PMID: 38626263 -
Pharmaceuticals (Basel)
New Assay Systems to Characterize the Broad-Spectrum Antiherpesviral and Non-Herpesviral Activity of Cyclin-Dependent Kinase (CDK) 8 Inhibitors. [Abstract]2025 Oct 16;18(10):1560. PMID: 41155676 -
Eur J Pharm Sci
FRET-based assay using a three-way junction DNA substrate to identify inhibitors of human cytomegalovirus pUL89 endonuclease activity. [Abstract]2019 Jan 15:127:29-37. PMID: 30342172
Ganciclovir purchased from MedChemExpress. Usage Cited in: Eur J Pharm Sci. 2019 Jan 15:127:29-37. [Abstract]
Viral reporter GFP expression after inoculation and compound treatment. Infected cells treated with DMSO control, BIO, Ganciclovir (GCV) or Letermovir (LTR)
-
J Gen Virol
Decoding the antiviral potential of eugenol, thymol and vanillin against human cytomegalovirus infection. [Abstract]2026 Mar;107(3):002248. PMID: 41849209 -
Antiviral Res
2021 Sep:193:105124. PMID: 34197862 -
J Virol
Inhibition of Human Cytomegalovirus pUL89 Terminase Subunit Blocks Virus Replication and Genome Cleavage. [Abstract]2017 Jan 18;91(3). pii: e02152-16. PMID: 27881652 -
Stem Cells
Transcriptomic analysis of the m6A reader YTHDF2 in the maintenance and differentiation of human embryonic stem cells. [Abstract]2025 Jun 24;43(7):sxaf032. PMID: 40418739 -
Microb Pathog
mTORC2-dependent autophagy inhibition regulates the replication of HSV-1 and adenovirus in viral keratitis & conjunctivitis. [Abstract]2026 Apr:213:108349. PMID: 41628839 -
Am J Physiol Gastrointest Liver Physiol
Regulatory T cells are induced by gut microbiota through differentially regulating costimulatory molecules of enteric glial cells. [Abstract]2026 May 1;330(5):G532-G548. PMID: 41711540 -
Pharmacol Res Perspect
Applicability of free drug hypothesis to drugs with good membrane permeability that are not efflux transporter substrates: A microdialysis study in rats. [Abstract]2020 Apr;8(2):e00575. PMID: 32266794 -
-
-
-
bioRxiv
Reprogramming the Immune Suppressive Tumor Microenvironment in Glioma Enhances the Efficacy of Immune-Mediated Gene Therapy. [Abstract]2025 Nov 13:2025.11.11.687828. PMID: 41293016 -
-
溶剤 & 溶解度
DMSO : 60 mg/mL (235.08 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 1.67 mg/mL (6.54 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.08 mg/mL (8.15 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (8.15 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 3.33 mg/mL (13.05 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (281 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Faulds D, et al. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs. 1990;39(4):597-638. [Content Brief]
[2]. Maggs DJ, et al. In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1. Am J Vet Res. 2004 Apr;65(4):399-403. [Content Brief]
[3]. Boujemla I, et al. Pharmacokinetics and tissue diffusion of ganciclovir in mice and rats. Antiviral Res. 2016;132:111-115. [Content Brief]
[4]. Fletcher CV, et al. Evaluation of ganciclovir for cytomegalovirus disease. DICP. 1989 Jan;23(1):5-12. [Content Brief]
[5]. Matthews T, et al. Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis. 1988 Jul-Aug;10 Suppl 3:S490-4. [Content Brief]
[6]. Duan J, Paris W, Kibler P, Bousquet C, Liuzzi M, Cordingley MG. Dose and duration-dependence of ganciclovir treatment against murine cytomegalovirus infection in severe combined immunodeficient mice. Antiviral Res. 1998;39(3):189-197. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 3.9180 mL | 19.5899 mL | 39.1797 mL | 97.9493 mL |
| 5 mM | 0.7836 mL | 3.9180 mL | 7.8359 mL | 19.5899 mL | |
| DMSO | 10 mM | 0.3918 mL | 1.9590 mL | 3.9180 mL | 9.7949 mL |
| 15 mM | 0.2612 mL | 1.3060 mL | 2.6120 mL | 6.5300 mL | |
| 20 mM | 0.1959 mL | 0.9795 mL | 1.9590 mL | 4.8975 mL | |
| 25 mM | 0.1567 mL | 0.7836 mL | 1.5672 mL | 3.9180 mL | |
| 30 mM | 0.1306 mL | 0.6530 mL | 1.3060 mL | 3.2650 mL | |
| 40 mM | 0.0979 mL | 0.4897 mL | 0.9795 mL | 2.4487 mL | |
| 50 mM | 0.0784 mL | 0.3918 mL | 0.7836 mL | 1.9590 mL | |
| 60 mM | 0.0653 mL | 0.3265 mL | 0.6530 mL | 1.6325 mL | |
| 80 mM | 0.0490 mL | 0.2449 mL | 0.4897 mL | 1.2244 mL | |
| 100 mM | 0.0392 mL | 0.1959 mL | 0.3918 mL | 0.9795 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.